[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 138
6. Gelos M, Behringer D, Philippou S, Mann B: Pancreatic carcinosarcoma. Case report of multimodal therapy and review of the literature. JOP; 2008;9(1):50-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic carcinosarcoma. Case report of multimodal therapy and review of the literature.
  • CONTEXT: Carcinosarcoma (malignant mixed tumor) is a rare variant of a pancreatic neoplasm having a dismal prognosis; very few clinical data and treatment options have been published.
  • Unlike adenocarcinoma of the pancreas, there is nothing specific in the literature for this variant regarding postoperative treatment with chemotherapeutic agents.
  • Examination revealed a mass in the pancreatic head and she underwent a partial pancreaticoduodenectomy.
  • Histopathological examination revealed a pancreatic neoplasm with both adenomatous as well as sarcomatous characteristics.
  • CONCLUSION: Carcinosarcoma of the pancreas is a very rare disease having a dismal prognosis.
  • In addition to reviewing the literature on this entity, we present the first published case where gemcitabine was administered as a treatment modality in combination with surgery.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinosarcoma / drug therapy. Carcinosarcoma / surgery. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Combined Modality Therapy. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Pancreaticoduodenectomy. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18182744.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  • [Number-of-references] 14
  •  go-up   go-down


7. Ang TL, Ng VW, Fock KM, Teo EK, Chong CK: Diagnosis of a metastatic phyllodes tumor of the pancreas using EUS-FNA. JOP; 2007;8(1):35-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of a metastatic phyllodes tumor of the pancreas using EUS-FNA.
  • Until now, there have been no published reports on the use of EUS-FNA to diagnose recurrent phyllodes tumors metastatic to the pancreas.
  • CASE REPORT: A 55-year-old female was hospitalized for the problem of painless obstructive jaundice due to a pancreatic head mass causing biliary obstruction.
  • She had a past history of a left breast phyllodes tumor treated with mastectomy.
  • The diagnostic dilemma was whether this was a case of primary pancreatic cancer or a recurrent phyllodes tumor presenting as a pancreatic metastasis.
  • EUS-FNA of the mass was performed and it revealed a metastatic phyllodes tumor.
  • The patient was treated with palliative biliary stenting and was referred for palliative chemotherapy.
  • CONCLUSION: This is the first report of a recurrent phyllodes tumor metastatic to the pancreas diagnosed using EUS-FNA.
  • It highlights the utility of EUS-FNA in characterizing the nature of pancreatic head masses.
  • [MeSH-major] Breast Neoplasms / pathology. Pancreatic Neoplasms / secondary. Phyllodes Tumor / secondary


8. Bachireddy P, Tseng D, Horoschak M, Chang DT, Koong AC, Kapp DS, Tran PT: Orthovoltage intraoperative radiation therapy for pancreatic adenocarcinoma. Radiat Oncol; 2010;5:105
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orthovoltage intraoperative radiation therapy for pancreatic adenocarcinoma.
  • Most tumors were located in the head of the pancreas (83%) and sites irradiated included: tumor bed (57%), vessels (26%), both the tumor bed/vessels (13%) and other (4%).
  • The majority of patients (83%) had IORT at the time of their definitive surgery.
  • Additional mean clinical characteristics include: age 64 (range 41-81); tumor size 4 cm (range 1.4-11); and IORT dose 1106 cGy (range 600-1500).
  • Post-operative external beam radiation (EBRT) or chemotherapy was given to 65% and 76% of the assessable patients, respectively.
  • Outcomes measured were infield control (IFC), loco-regional control (LRC), distant metastasis free survival (DMFS), overall survival (OS) and treatment-related complications.
  • Our cohort had three grade 3-5 complications associated with treatment (surgery and IORT).
  • CONCLUSIONS: Orthovoltage IORT following tumor reductive surgery is reasonably well tolerated and seems to confer in-field control in carefully selected patients.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Intraoperative Period. Kaplan-Meier Estimate. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4 [10615932.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):734-42 [20207498.001]
  • [Cites] Lancet. 2001 Nov 10;358(9293):1576-85 [11716884.001]
  • [Cites] Am J Clin Oncol. 2003 Feb;26(1):16-21 [12576918.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Oct;12(4):899-924 [14989123.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1249-51 [15028829.001]
  • [Cites] Lancet. 2004 Mar 27;363(9414):1049-57 [15051286.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 Oct;10(10):1957-65 [6490425.001]
  • [Cites] Arch Surg. 1985 Aug;120(8):899-903 [4015380.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Feb;12(2):255-9 [3949576.001]
  • [Cites] Cancer. 1987 Jun 15;59(12):2006-10 [3567862.001]
  • [Cites] Arch Surg. 1989 Jan;124(1):127-32 [2910241.001]
  • [Cites] Int J Pancreatol. 1990 Aug-Nov;7(1-3):195-200 [2081924.001]
  • [Cites] Cancer. 1994 Jun 15;73(12):2930-5 [8199990.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3 [7794076.001]
  • [Cites] Br J Cancer. 1997;76(11):1474-9 [9400944.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(3):227-34 [9880768.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):965-6 [15752874.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Acta Oncol. 2006;45(2):124-35 [16546857.001]
  • [Cites] Semin Oncol. 2007 Aug;34(4):335-46 [17674962.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):504-11 [17560736.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1094-9 [18313525.001]
  • [Cites] Radiother Oncol. 2008 Jun;87(3):318-25 [18199514.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3503-10 [18640931.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3511-6 [18640932.001]
  • [Cites] Radiother Oncol. 2009 Apr;91(1):54-9 [18762346.001]
  • [Cites] J Clin Oncol. 2009 Jun 10;27(17):2855-62 [19398572.001]
  • [Cites] Ann Surg Oncol. 2009 Aug;16(8):2116-22 [19437078.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):651-8 [11395232.001]
  • (PMID = 21059255.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2987939
  •  go-up   go-down


9. Ogawa B, Okinaga K, Obana K, Nakamura K, Hattori T, Ito T, Yanagawa Y, Tanaka F, Imamura T: Pancreatoblastoma treated by delayed operation after effective chemotherapy. J Pediatr Surg; 2000 Nov;35(11):1663-5
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatoblastoma treated by delayed operation after effective chemotherapy.
  • Computed tomography scan showed a 10- x 8- x 7-cm mass occupying both the head and body of the pancreas.
  • Results of open biopsy of the tumor showed pancreatoblastoma.
  • Chemotherapy was administered using the new A-1 regimen consisting of cyclophosphamide, etoposide, pirarubicin, and cisplatin.
  • After 3 cycles of chemotherapy, the size of the tumor was reduced to 5 x 4 x 3 cm, the portal vein became patent, and the AFP value decreased to 98.1 ng/mL.
  • Total removal of the tumor was performed leaving the head and tail of the pancreas.
  • Postoperative chemotherapy continued for 2 years.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Neoplasms, Germ Cell and Embryonal / drug therapy. Neoplasms, Germ Cell and Embryonal / surgery. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Biopsy, Needle. Child, Preschool. Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Pancreatectomy / methods. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatoblastoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11083448.001).
  • [ISSN] 0022-3468
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; D58G680W0G / pirarubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Tsuruta K, Okamoto A, Egawa N, Kamisawa T, Karasawa K, Takahashi T: Survival benefits of adjuvant chemotherapy with oral doxifluridine (5'-DFUR) following radiotherapy in patients with unresectable pancreatic cancer. J Surg Oncol; 2001 Nov;78(3):202-7
Hazardous Substances Data Bank. FLOXURIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival benefits of adjuvant chemotherapy with oral doxifluridine (5'-DFUR) following radiotherapy in patients with unresectable pancreatic cancer.
  • BACKGROUND AND OBJECTIVES: The combination of 5-fluorouracil and radiotherapy is thought to be the most effective treatment for locally unresectable pancreatic carcinoma.
  • We assessed the survival benefits of oral adjuvant chemotherapy with doxifluridine (5'-DFUR) following radiotherapy for patients with the disease.
  • METHODS: Thirty-five consecutive patients who underwent bypass surgery and radiotherapy for localized advanced unresectable adenocarcinoma of the pancreas head were retrospectively reviewed in regard to disease progression and survival.
  • Ten of the 35 patients underwent adjuvant chemotherapy with 5'-DFUR after radiotherapy in an outpatient setting.
  • The 1-, 2-, and 3-year survivals for patients treated with the adjuvant chemotherapy after radiotherapy were 50, 40, and 30%, respectively (P = 0.0069, log-rank test).
  • The elevation of tumor markers was delayed (P = 0.0346) and local control rate was improved (P = 0.0475) in patients with chemotherapy.
  • Multivariate analysis demonstrated that the adjuvant chemotherapy with 5'-DFUR was a significant independent prognostic factor as well as tumor size.
  • CONCLUSIONS: The adjuvant chemotherapy with 5'-DFUR following radiotherapy led to a significant prolongation of the survival for patients with unresectable localized pancreatic cancer.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Floxuridine / administration & dosage. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / radiotherapy
  • [MeSH-minor] Administration, Oral. Aged. Chemotherapy, Adjuvant. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Prognosis. Radiotherapy Dosage. Retrospective Studies. Survivors

  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11745808.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 039LU44I5M / Floxuridine; V1JK16Y2JP / doxifluridine
  • [Number-of-references] 21
  •  go-up   go-down


11. Homma H, Kukitsu T, Mezawa S, Doi T, Kida M, Miyanishi K, Takada K, Murase K, Iyama S, Niitsu Y: [Hepatic and splenic arterial infusion chemotherapy after transcatheter peripancreatic arterial embolization for patients with inoperable adenocarcinoma of the pancreas]. Gan To Kagaku Ryoho; 2001 Oct;28(11):1558-61
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hepatic and splenic arterial infusion chemotherapy after transcatheter peripancreatic arterial embolization for patients with inoperable adenocarcinoma of the pancreas].
  • Thirty-one patients with advanced pancreatic carcinoma and liver metastases were treated by hepatic and splenic arterial infusion chemotherapy after transcatheter peripancreatic arterial embolization.
  • By site of the primary tumor, the response rate for pancreatic head and body carcinoma was 81%, with a mean survival period of 21.6 +/- 4.0 months and a 50% survival period of 17 months, whereas the response rate for pancreatic caudal carcinoma was 20%, with a mean survival period of 6.1 +/- 0.5 months and a 50% survival period of 6 months.
  • We believe that the current chemotherapy is an effective treatment for advanced pancreatic cancer with liver metastases.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Chemoembolization, Therapeutic / methods. Liver Neoplasms / secondary. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Hepatic Artery. Humans. Infusions, Intra-Arterial. Middle Aged. Pancreas / blood supply. Splenic Artery. Survival Rate

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11707979.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


12. Kobayashi M, Kasakura Y, Fujii M, Mochizuki F, Kochi M, Eguchi T, Imai S: [Curative resection of advanced gastric cancer responding to preoperative chemotherapy--a case report]. Gan To Kagaku Ryoho; 2001 Apr;28(4):527-30
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Curative resection of advanced gastric cancer responding to preoperative chemotherapy--a case report].
  • A 56-year-old male was admitted for treatment of advanced gastric cancer.
  • The patient was diagnosed as having an unresectable advanced gastric cancer because cancer cells had invaded the pancreas head and there were metastatic lymph nodes.
  • The patient underwent preoperative chemotherapy (FLEP: intra-arterial infusion of CDDP, ETP and intravenous infusion of 5-FU, LV).
  • The primary tumor and metastatic lymph nodes were reduced by three course of chemotherapy.
  • Preoperative chemotherapy using FLEP was performed in 15 patients with unresectable primary advanced gastric cancer.
  • This therapy resulted in significantly higher survival times.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Infusion Pumps, Implantable. Neoadjuvant Therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Etoposide / administration & dosage. Fluorouracil / administration & dosage. Gastrectomy. Humans. Leucovorin / administration & dosage. Male. Middle Aged. Preoperative Care

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11329789.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; FLEP regimen
  •  go-up   go-down


13. Miura T: [Intra-arterial infusion chemotherapy for advanced cancer--40 years of experience]. Gan To Kagaku Ryoho; 2005 Oct;32(11):1618-22
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intra-arterial infusion chemotherapy for advanced cancer--40 years of experience].
  • In 70% of the patients treated, an objective response was observed with marked regression of tumor and decrease in tumor marker (AFP and PIVKA-II).
  • Also 1,091 patients with the metastatic liver cancer of colon, rectum, stomach and pancreas were treated with the same procedure employing 5-FU, mitomycin C, adriamycin, or epi-adriamycin.
  • In more than 80% of the patients treated, an objective response was observed with marked regression of tumor and decrease in tumor marker (CEA, CA19-9, TPA, DUPAN-2, SPan-1).
  • Intra-arterial infusion chemotherapy employing an implantable port system also proved to be a promising treatment modality for most of the intractable head and neck cancer, breast cancer and a few of the pancreas cancer.
  • [MeSH-major] Carcinoma, Hepatocellular / drug therapy. Infusions, Intra-Arterial / instrumentation. Liver Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Breast Neoplasms / drug therapy. Head and Neck Neoplasms / drug therapy. Humans. Infusion Pumps. Pancreatic Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16315888.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


1
Advertisement
4. Sugimoto K, Okada K, Nakahira S, Okamura S, Miki H, Nakata K, Suzuki R, Yoshimura M, Uji K, Yoshida A, Tamura S: [A case of metastatic pancreatic cancer after combination chemotherapy with uracil-tegafur and gemcitabine]. Gan To Kagaku Ryoho; 2009 Feb;36(2):321-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of metastatic pancreatic cancer after combination chemotherapy with uracil-tegafur and gemcitabine].
  • We report a case of pancreas head cancer with liver metastasis treated with uracil-tegafur (UFT) and gemcitabine combined chemotherapy.
  • The histopathological diagnosis was adenocarcinoma, so we inserted a self-expandable metallic stent (EMS) in this inoperable pancreas head cancer.
  • We performed 9 courses of UFT and gemcitabine (GEM) combination chemotherapy.
  • Renewed liver metastases did not appear, and the pancreas head tumor partially responded.
  • After treatment with an additional 11 courses of chemotherapy, he took S-1 orally because of a tumor recurrence.
  • Combination chemotherapy and surgery enhanced the survival benefit in this case.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology. Tegafur / therapeutic use. Uracil / therapeutic use
  • [MeSH-minor] Aged. Combined Modality Therapy. Fatal Outcome. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19223756.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


15. Jin C, Yao L, Long J, Fu DL, Yu XJ, Xu J, Yang F, Ni QX: Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma. Chin Med J (Engl); 2009 Feb 5;122(3):284-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma.
  • BACKGROUND: Regional intra-arterial infusion chemotherapy (RIAC) has been more valuable to improve prognosis and quality of life of patients with inoperable pancreatic adenocarcinomas, and adjuvant RIAC plays an important role in prolonging survival and reducing risk of liver metastasis after radical resection of pancreatic cancer, but the effect of preoperative or multiple-phase RIAC (preoperative combined with postoperative RIAC) for resectable pancreatic cancers has not been investigated.
  • In this prospective study, the effect of multiple-phase RIAC for patients with resectable pancreatic head adenocarcinoma was evaluated, and its safety and validity comparing with postoperative RIAC were also assessed.
  • METHODS: Patients with resectable pancreatic head cancer were randomly assigned to two groups.
  • Patients in group A (n=50) were treated with new therapeutic mode of extended pancreaticoduodenectomy combined with multiple-phase RIAC, and those in group B (n=50) were treated with extended pancreaticoduodenectomy combined with postoperative RIAC in the same period.
  • The feasibility, compliance and efficiency of the new therapeutic mode were evaluated by tumor size, serum tumor markers, clinical benefit response (CBR), surgical complications, mortality and toxicity of RIAC.
  • The disease-free survival time, median survival time, incidence of liver metastasis, survival rate at 1, 2, 3 and 5 years were also observed.
  • Serum tumor markers decreased obviously and tumors size decreased in 26% of patients after preoperative RIAC in group A.
  • The disease-free survival time and median survival time in group A were 15.5 months and 18 months respectively.
  • There was no significant difference of survival time or survival rates between two groups.
  • CONCLUSIONS: Multiple-phase RIAC is effective in combined therapy of resectable pancreatic head carcinomas by enhancing inhibition of tumor growth and reduction of liver metastasis, without negative effect on patients' safety or surgical procedure.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Infusions, Intra-Arterial / methods. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Disease-Free Survival. Female. Fluorouracil / therapeutic use. Humans. Liver Neoplasms / secondary. Male. Middle Aged. Mitomycin / therapeutic use. Neoplasm Metastasis. Pancreas / drug effects. Pancreas / pathology. Pancreas / surgery. Pancreaticoduodenectomy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19236805.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 50SG953SK6 / Mitomycin; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


16. Chiappori A, Simon GR, Kvols L, Tetteh L, Mahany JJ, Lush R, Sullivan DM: Phase I trial of carboplatin, irinotecan and etoposide in advanced solid tumors. J Clin Oncol; 2004 Jul 15;22(14_suppl):2132

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Carboplatin(C), Irinotecan(T) and Etoposide (E) are drugs with a broad spectrum of activity.
  • RESULTS: A total of 10 patients were enrolled from April 2002 to October 2002.Patient characteristics were M/F 5/5; age range 24 to 65, ECOG PS 0/1=1/9; number of prior treatments 0/1/2/3= 4/2/3/1; median number of cycles given=3 (range 1 - 8).
  • Tumor types enrolled were NSCLC = 3, Carcinoid = 3, and 1 each of Head and Neck Cancer, Mesothelioma, Sarcoma and Islet Cell Cancer of the pancreas.
  • The subsequent cohort of 6 patients tolerated chemotherapy well with no first-cycle or second-cycle grade III or IV neutropenia or thrombocytopenia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016906.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Viret F, Ychou M, Baey C, Bennouna J, Adenis A, Peiffert D, Mornex F, Celier P, Montoto-Grillot C, Ducreux M: A phase II study of radiation and docetaxel and cisplatin in the treatment of locally advanced pancreatic carcinoma. FNCLCC-ACCORD 09 /0201 trial. J Clin Oncol; 2009 May 20;27(15_suppl):4625

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of radiation and docetaxel and cisplatin in the treatment of locally advanced pancreatic carcinoma. FNCLCC-ACCORD 09 /0201 trial.
  • : 4625 Background: Locally advanced pancreatic carcinoma remains a challenging tumor with no clear standard of care in terms of radio-chemotherapy.
  • The purpose of this phase II trial was to determine the efficacy and the toxicity of radiotherapy and docetaxel and cisplatin in histologically proven adenocarcinoma of the pancreas.
  • METHODS: Patients (pts) received external beam radiotherapy (54 Gy in 1.8 Gy fractions, six weeks) and weekly chemotherapy regimen of association docetaxel and cisplatine (20 mg/m<sup>2</sup>/weeks each) for six weeks.
  • RESULTS: 51 pts (20 women and 31 men, with median age of 62 years) with disease considered to be unresectable but confined to pancreas area and celiac nodes were included between 06/10/2003 and 15/02/2008.
  • Location of the tumor: head (33 pts), body (13 pts), and tail (5 pts).
  • The median dose of radiotherapy received by the patients was 54 Gy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964209.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Dudek A, Larson T, Mellskog CE, Bloss LP, Obasaju C: A phase I clinical study of biweekly pemetrexed and gemcitabine in patients with advanced solid tumors. J Clin Oncol; 2004 Jul 15;22(14_suppl):2141

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The optimal sequence and schedule of both drugs is currently unknown.
  • Dose Escalation Levels with DLTs [Figure: see text] Results: Thus far, 24 patients (13 female, 11 male) with 1 or no prior chemotherapy; median age 61 (range 39 - 80); ECOG PS 0 (11), 1 (13); diagnoses: lung (10), malignant pleural mesothelioma (3), pancreas (3), breast (2), atypical carcinoid tumor (2), head and neck (1), ovarian (1), skin (1), unknown primary (1) have received a current total of 87 cycles (range 1-13/ patient).
  • Plans are to study this schedule in phase 2 trials in many tumor types where G and P are known to be active.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016894.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Graefe T, Lubbing C, Bolling C, Muller-Hagen S, Leisner B, Fleet J, Ludtke FE, Blatter J, Suri A, Hanauske AR: Phase I study of pemetrexed plus paclitaxel in patients with solid tumor. J Clin Oncol; 2004 Jul 15;22(14_suppl):2103

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of pemetrexed plus paclitaxel in patients with solid tumor.
  • RESULTS: 45 pts [31 M, 14 F; median age 59 (range 31-77); WHO performance status 0-1 (86.7%); prior chemotherapy (53.3%)] were enrolled.
  • Three drug-related discontinuations were anorexia, thrombocytopenia, and pancytopenia.
  • Four pts died while on study (1 nondrug-related; 1 gastric ulcer hemorrhage, 1 sepsis, and 1 tumor lysis).
  • Stable disease occurred in pts with mesothelioma (3) and esophagus (2) cancers, and 1 pt each with thyroid, head and neck, lung, liver, pancreas, prostate, renal, and stomach cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28017047.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Denno R, Sasada T, Kanai M, Takabayashi A: Phase II trials of pancreatic and hepatic arterial infusion of 5-fluorouracil (5-FU) and cisplatin (CDDP) in patients with advanced pancreatic cancer with or without liver metastasis. J Clin Oncol; 2004 Jul 15;22(14_suppl):4140

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to examine the efficacy and safety of a modality therapy consisting of pancreatic and hepatic arterial infusion of 5-FU and CDDP in patients with advanced pancreatic cancer with or without liver metastasis.
  • To restrict the blood flow into the pancreas and the liver, the peripancreatic artery (ex. dorsal pancreatic artery) were embolized superselectively with microcoils.
  • The tip of the catheter was placed in the proper hepatic artery and the side hole was placed in the gastroduodenal artery for the patients of pancreas head cancer.
  • The splenic artery and the common hepatic artery were used for the patients of pancreas body or tail cancer.
  • The patients of Group A received both hepatic and pancreatic arterial injection chemotherapy to prevent liver metastasis.
  • The arterial infusion chemotherapy consisted of 5-FU 250 mg/sqm administration as a 24-hr continuous arterial infusion and a bolus injection of CDDP 5mg/sqm three times a week for two weeks to all 12 patients.
  • Median survival time was 16.3 months for Group A and 6.1 months for Group B.
  • One of Group A had liver metastasis after this treatment.
  • CONCLUSIONS: In patients with unresectable pancreatic cancer, hepatic and pancreatic arterial injection chemotherapy after hemodynamic change is effective to treat main pancreatic tumor and to prevent liver metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014545.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Yoneto T, Yoshikawa K, Fujii Y: [A patient with recurrent gallbladder cancer responding to chemotherapy with CDDP/CPT-11 and gemcitabine]. Gan To Kagaku Ryoho; 2005 Jan;32(1):99-102
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A patient with recurrent gallbladder cancer responding to chemotherapy with CDDP/CPT-11 and gemcitabine].
  • A 79-year-old female patient was referred to our hospital for treatment of a recurrent gallbladder cancer.
  • Before admission, she had undergone expanded cholecystectomy and had been treated successfully with 5-FU for 3 years to suppress the tumor growth in intraperitoneal lymph nodes.
  • The recurrence of the tumor in lymph nodes near the pancreas head was demonstrated by computer tomography.
  • We tried a course of a combination chemotherapy consisting of CPT-11 and CDDP (40 mg CPT-11/body/day on day 1 and 10 mg CDDP/body/day on day 2-5) to reduce the size of the nodes.
  • Then, we repeated a total of 8 courses of the therapy at 4-week intervals.
  • So, we substituted gemcitabine (1 g/body/day) for the combination chemotherapy with expandable metallic stent implantation to drain the bile.
  • Thereafter, the patient was given an additional 20 courses of gemcitabine therapy at 2-week intervals as an outpatient.
  • However, the patient died of liver metastasis 8 years after operation and 6 years after she started chemotherapy for the recurrence.
  • She maintained a good quality of life during that time.
  • The present case suggests that combination of chemotherapy protocols is effective for clinical management of gallbladder cancer recurrence, which is generally considered to be difficult to manage with chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Deoxycytidine / analogs & derivatives. Gallbladder Neoplasms / drug therapy. Lymph Nodes / pathology. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Drug Administration Schedule. Female. Humans. Lymphatic Metastasis. Survivors

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15675592.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 7673326042 / irinotecan; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


22. Oshiro A, Nagasaki A, Nakachi A, Uchima N, Hasegawa H, Nakazato T, Nakamoto M, Kinjo N, Kinjo F, Taira N, Masuda M, Takasu N: [A case of primary malignant lymphoma of the duodenum successfully treated with dose escalating chemotherapy]. Gan To Kagaku Ryoho; 2003 Aug;30(8):1169-73
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary malignant lymphoma of the duodenum successfully treated with dose escalating chemotherapy].
  • A 65-year-old woman with diabetes mellitus was hospitalized for heart failure and anemia in August 2001, and recovered with conservative treatment.
  • Abdominal CT scan demonstrated tumor involvement in the pancreas head.
  • The diagnosis of a diffuse large B-cell lymphoma, clinical stage IIE, was made by endoscopic biopsy.
  • Although surgical resection of the localized intestinal tumor would have been a common choice for initial treatment, polychemotherapy was selected; the patient had diabetes mellitus and preferred polychemotherapy to surgical operation.
  • Because of bulky intestinal mass, transmural disease and sensitive histological type, standard-dose chemotherapy was considered to include a high risk of intestinal perforation.
  • We performed dose-escalating chemotherapy: A half dose of THP-COP (pirarubicin, cyclophosphamide, vincristine) was given at the start in October 2001, 60% THP-COP as the next cycle, 80% THP-COP as the 3rd cycle and thereafter.
  • Without serious complications of the intestine, she received a total of 6 cycles of chemotherapy and subsequent involved field radiation.
  • There has been no evidence of recurrence of disease 14 months from the start of chemotherapy.
  • When conditions make surgical treatment difficult, dose-escalating chemotherapy in a treatment cycle may be considered as an alternative.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Duodenal Neoplasms / drug therapy. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Prednisolone / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Aged. Female. Humans. Treatment Outcome

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12938276.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VEP-THP protocol
  •  go-up   go-down


23. Katsumata K, Tomioka H, Sumi T, Yamasaki T, Takagi M, Kato F, Suzuki Y, Aoki T, Koyanagi Y: Liver metastasis of pancreatic cancer managed by intra-arterial infusion chemotherapy combined with degradable starch microspheres. Int J Clin Oncol; 2003 Apr;8(2):110-2
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver metastasis of pancreatic cancer managed by intra-arterial infusion chemotherapy combined with degradable starch microspheres.
  • A patient with liver metastasis of pancreatic cancer received chemotherapy using mitomycin C and degradable starch microspheres.
  • The patient was a 52-year-old woman who had undergone surgery for cancer of the head of the pancreas in October 1996.
  • She had stage III disease and was followed up as an outpatient on oral therapy with a combined uracil and tegafur preparation.
  • In October 2000, abdominal computed tomography (CT) scans detected multiple liver metastases.
  • Three courses of intra-arterial infusion of mitomycin C and microspheres (1000 mg) resulted in regression of her tumor and a decrease of tumor marker levels.
  • After three more courses of this therapy, the patient developed bile duct necrosis and died of disseminated intravascular coagulation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Bile Duct Diseases / chemically induced. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / secondary. Doxorubicin / analogs & derivatives. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Pancreatic Neoplasms / pathology. Starch / adverse effects
  • [MeSH-minor] Chemoembolization, Therapeutic / adverse effects. Chemoembolization, Therapeutic / methods. Chemotherapy, Adjuvant. Combined Modality Therapy. Fatal Outcome. Female. Humans. Infusions, Intra-Arterial. Middle Aged. Mitomycin / administration & dosage. Mitomycin / adverse effects. Necrosis. Neoplasm Staging. Pancreaticoduodenectomy / methods. Risk Assessment. Tomography, X-Ray Computed


24. Kim DH, Shiozawa S, Tsuchiya A, Usui T, Inose S, Aizawa M, Yoshimatsu K, Katsube T, Naritaka Y, Ogawa K: [Chemotherapy with gemcitabine after non-curative resection of bile duct cancer--a case report]. Gan To Kagaku Ryoho; 2008 Jul;35(7):1229-31
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy with gemcitabine after non-curative resection of bile duct cancer--a case report].
  • We present a case successfully treated with gemcitabine for residual tumor after extra hepatic bile duct resection with positive surgical margin.
  • Although additional resection of bile duct was done, pathological diagnosis resulted in positive margin again.
  • Adjuvant chemotherapy with gemcitabine(800 mg/m2 on days 1, 8 and 15 every 4 weeks)was started at the seventh postoperative day.
  • A residual lesion was shown in the pancreas head by abdominal CT after 2 courses of chemotherapy.
  • The chemotherapy has been continued up to the present(3 years and 5 months after surgery).
  • [MeSH-major] Bile Duct Neoplasms / drug therapy. Bile Duct Neoplasms / pathology. Deoxycytidine / analogs & derivatives
  • [MeSH-minor] Aged. Humans. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633270.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


25. Hoshino H, Takeda Y, Nagano H, Nakamori S, Kobayashi S, Eguchi H, Marubashi S, Tanemura M, Kitagawa T, Umeshita K, Monden M, Doki Y, Mori M: [A long-term survival case of pancreatic cancer with hepatic metastasis after pancreaticoduodenectomy successfully treated by s-1 and gemcitabine combination chemotherapy]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2419-21
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A long-term survival case of pancreatic cancer with hepatic metastasis after pancreaticoduodenectomy successfully treated by s-1 and gemcitabine combination chemotherapy].
  • Gemcitabine monotherapy is accepted as a standard first-line treatment for locally advanced unresectable or metastatic pancreatic cancer.
  • On another front, S-1 and gemcitabine combination chemotherapy is challenging but promising.
  • We report a long-term survival case of pancreatic cancer with hepatic metastasis after surgical resection treated by S-1 and gemcitabine combination chemotherapy.
  • A 59-year-old woman was diagnosed as locoregionally advanced pancreas head cancer without metastatic disease.
  • The patient received 35 courses of S-1 and gemcitabine combination therapy.
  • The metastatic tumor was disappeared, and serum CEA decreased to a normal level.
  • S-1 and gemcitabine combination therapy is not only effective but also well tolerated and safe.
  • This combination therapy should be considered one of selective choices for advanced or metastatic pancreatic cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Pancreatic Neoplasms / therapy. Pancreaticoduodenectomy
  • [MeSH-minor] Antimetabolites, Antineoplastic / administration & dosage. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drug Combinations. Female. Humans. Middle Aged. Oxonic Acid / administration & dosage. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer 1.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037442.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0W860991D6 / Deoxycytidine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


26. Nio Y, Itakura M, Koike M, Omori H, Hashimoto K, Yano S, Higami T: A self-expandable metallic stent in combination with cholangioscopic microwave coagulation therapy and chemotherapy with oral TS-1 against obstructive jaundice due to recurrent gastric cancer: a case report of successful treatment. Anticancer Res; 2003 Mar-Apr;23(2C):1795-801
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A self-expandable metallic stent in combination with cholangioscopic microwave coagulation therapy and chemotherapy with oral TS-1 against obstructive jaundice due to recurrent gastric cancer: a case report of successful treatment.
  • A 45-year-old female patient had a recurrent gastric cancer at the pancreas head and it caused obstructive jaundice.
  • She was treated with percutaneous transhepatic cholangio-drainage, followed by radiotherapy and chemotherapy with cisplatin, epirubicin and 5-FU, which resulted in a prominent response and a self-expandable metallic stent was placed into the bile duct.
  • After 11 months, however, the tumor recurred and the bile duct was obstructed again by an invading tumor.
  • She was retreated with percutaneous transhepatic cholangio-drainage for jaundice, followed by chemotherapy with oral TS-1.
  • Her recurrent tumor dramatically responded again, and cholangioscopic microwave coagulation therapy was applied for the first time through a cholangio-drainage route and an additional metallic stent was inserted into the bile duct.
  • After these therapies she has been disease--free for more than 2 years.
  • In conclusion, the placement of a self-expandable metallic stent in combination with cholangioscopic microwave coagulation therapy and TS-1 was very effective in managing the obstructive jaundice due to the local recurrence of gastric cancer.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Cholestasis, Extrahepatic / therapy. Microwaves / therapeutic use. Neoplasm Recurrence, Local / complications. Oxonic Acid / therapeutic use. Pyridines / therapeutic use. Stents. Stomach Neoplasms / complications. Tegafur / therapeutic use
  • [MeSH-minor] Administration, Oral. Bile Ducts / surgery. Cautery / methods. Combined Modality Therapy. Drainage. Drug Combinations. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Oral cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12820461.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


27. Oshiro Y, Moon Y, Yamamoto Y, Aita K: [A resected case of stage IV gastric cancer successfully treated with TS-1/CDDP as neoadjuvant chemotherapy]. Gan To Kagaku Ryoho; 2006 May;33(5):667-70
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A resected case of stage IV gastric cancer successfully treated with TS-1/CDDP as neoadjuvant chemotherapy].
  • The patient was a 60-year-old woman who presented a type 3 gastric tumor complicated by invasion of the head of the pancreas and liver.
  • Radical resection was not indicated, and we administered the following combination chemotherapy with TS-1 and CDDP.
  • 120 mg/day of TS-1 was orally administered for 3 weeks followed by 2 drug-free weeks as 1 course and 9 5 mg (60 mg/m(2)) of CDDP was administered intravenously on day 8.
  • TS-1/CDDP therapy is useful for advanced gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrectomy. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery
  • [MeSH-minor] Cisplatin / administration & dosage. Drug Administration Schedule. Drug Combinations. Female. Humans. Lymph Node Excision. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16685169.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


28. Takagi T, Ueda N, Kanemoto H: [Effective treatment of unresectable advanced gastric cancer by TS-1-based chemotherapy with a sequential combination of cisplatin (CDDP) and paclitaxel (PTX)]. Gan To Kagaku Ryoho; 2005 Oct;32(10):1453-6
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effective treatment of unresectable advanced gastric cancer by TS-1-based chemotherapy with a sequential combination of cisplatin (CDDP) and paclitaxel (PTX)].
  • The patient was a 66-year-old female with Borrmann's type 4 gastric cancer complicated by metastasis to the liver and invasion of the head of the pancreas.
  • One course of chemotherapy was defined as 3 weeks of drug administration(TS-1 100 mg/body/day po for 21 days + CDDP 9 0 mg/body/day by iv drip on day 8), followed by a 2-week rest period.
  • Chemotherapy was started 13 days after the operation, and it was possible to continue it for 7 courses.
  • TS-1/CDDP therapy improved the patient's general condition.
  • The tumor marker levels were also decreased.
  • However, the efficacy of treatment began to decline,and ascites gradually developed during the fourth course of therapy.
  • The treatment regimen was then switched to TS-1 100 mg/body/day po for 14 days, followed by a 14-day rest period, combined with PTX 9 0 mg/body/day iv drip on day 1 and day 15, while the ascites was being controlled.
  • However, PTX was switched to CPT-11 because of gradual progression of peripheral neuropathy as a side effect of chemotherapy, and the patient subsequently died without any improvement in symptoms.
  • This report describes a case of advanced gastric cancer treated by combination chemotherapy with TS-1 as a key drug, which resulted in a long survival (1 year and 5 months)and improvement in quality of life.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Drug Administration Schedule. Drug Combinations. Female. Humans. Liver Neoplasms / secondary. Neoplasm Invasiveness. Oxonic Acid / administration & dosage. Paclitaxel / administration & dosage. Pancreatic Neoplasms / pathology. Pyridines / administration & dosage. Quality of Life. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16227747.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


29. Wanebo HJ, Glicksman AS, Vezeridis MP, Clark J, Tibbetts L, Koness RJ, Levy A: Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer. Arch Surg; 2000 Jan;135(1):81-7; discussion 88
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer.
  • HYPOTHESIS: Neoadjuvant therapy has the potential to induce regression of high-risk, locally advanced cancers and render them resectable.
  • Preoperative chemoradiotherapy is proposed as a testable treatment concept for locally advanced pancreatic cancer.
  • A course of chemotherapy with fluorouracil and cisplatin plus radiotherapy was then initiated.
  • Reexploration and resection were planned subsequent to neoadjuvant therapy.
  • MAIN OUTCOME MEASURES: Tumor regression and survival.
  • INTERVENTIONS: Surgically staged patients with locally advanced pancreatic cancer were treated by preoperative chemotherapy with bolus fluorouracil, 400 mg/m2, on days 1 through 3 and 28 through 30 accompanied by a 3-day infusion of cisplatin, 25 mg m2, on days 1 through 3 and 28 through 30 and concurrent radiotherapy, 45 Gy.
  • RESULTS: Of 14 patients who enrolled in the protocol and were initially surgically explored, 3 refused the second operation and 11 were reexplored; 2 showed progressive disease and were unresectable and 9 (81%) had definitive resection.
  • One patient who was considered too frail for resection had core biopsies of the pancreatic head, node dissection, and an interstitial implant of the tumorous head.
  • Pathologic response: 2 patients had apparent complete pathologic response; 1 patient had no residual cancer in the pancreatectomy specimen, the other patient who had an iridium 192 interstitial implant had normal core biopsies of the pancreatic head.
  • Five patients had minimal residual cancer in the resected pancreas or microscopic foci only with extensive fibrosis, and 2 patients had fully viable residual cancer.
  • In the definitive surgery group the median survival was 19 months after beginning chemoradiotherapy and 16 months after definitive surgery.
  • [MeSH-major] Neoadjuvant Therapy. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brachytherapy. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Pancreas / pathology. Radiotherapy Dosage. Reoperation. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10636353.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


30. Tanaka T, Yamamoto K, Sho M, Nishiofuku H, Inoue M, Sueyoshi S, Anai H, Sakaguchi H, Nakajima Y, Kichikawa K: Pharmacokinetic evaluation of pancreatic arterial infusion chemotherapy after unification of the blood supply in an animal model. J Vasc Interv Radiol; 2010 Jan;21(1):116-21
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacokinetic evaluation of pancreatic arterial infusion chemotherapy after unification of the blood supply in an animal model.
  • PURPOSE: The purpose of this study was to investigate the potential pharmacokinetic advantage of pancreatic arterial infusion chemotherapy of 5-fluorouracil (5-FU) with temporary unification of the pancreatic blood supply for advanced pancreatic cancer in an animal model.
  • At 0, 10, 30, and 60 minutes after drug infusion, the concentrations of 5-FU were measured in plasma and tissues including the liver, pancreatic head, pancreatic uncinate process, and duodenum.
  • Areas under the concentration-time curve (AUCs) were calculated and statistically compared.
  • Mean AUCs in the pancreas head and liver were significantly higher for groups II and III compared with group I (P < .05).
  • CONCLUSIONS: Pancreatic arterial infusion chemotherapy allows efficient regional drug delivery into the pancreas and liver.
  • Importantly, the unification of the pancreatic blood supply may be required to induce maximum efficacy of arterial infusion chemotherapy for the tumor in the pancreatic uncinate process.
  • [MeSH-major] Arteries / metabolism. Arteries / surgery. Fluorouracil / pharmacokinetics. Pancreas / blood supply. Pancreas / metabolism
  • [MeSH-minor] Animals. Antimetabolites, Antineoplastic / pharmacokinetics. Humans. Infusions, Intra-Arterial. Metabolic Clearance Rate. Organ Specificity. Swine. Tissue Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20123197.001).
  • [ISSN] 1535-7732
  • [Journal-full-title] Journal of vascular and interventional radiology : JVIR
  • [ISO-abbreviation] J Vasc Interv Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


31. Takeyama O, Usui Y: [Two-year survivor in response to gemcitabine-based chemotherapy for advanced pancreatic cancer with multiple lung metastases]. Gan To Kagaku Ryoho; 2005 Feb;32(2):247-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two-year survivor in response to gemcitabine-based chemotherapy for advanced pancreatic cancer with multiple lung metastases].
  • Abdominal CT scan and ultrasonography both revealed a tumor in the head of the pancreas.
  • The primary tumor showed a partial response to the administration of gemcitabine 1,000 mg/m2 on days 1, 8 and 15 of a 28-day cycle.
  • Concurrent treatment with 5-fluorouracil (200 mg/day) was efficacious against the lung metastases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Lung Neoplasms / drug therapy. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. CA-19-9 Antigen / blood. Cisplatin / administration & dosage. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Quality of Life. Survivors

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15751643.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / CA-19-9 Antigen; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


32. Imamura H, Furukawa H, Kishimoto T, Miyazaki Y, Ohta K, Yamamoto T, Takemoto H, Fukunaga M, Ohsato H, Tatsuta M: [A case of advanced gastric cancer treated with chemo-radiotherapy as the fourth-line therapy]. Gan To Kagaku Ryoho; 2008 Nov;35(12):2054-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer treated with chemo-radiotherapy as the fourth-line therapy].
  • A 69-year-old female patient with type 2 advanced gastric cancer (s-T4N0M0H0Cy0P0, f-Stage IIIA) located from lower corps to antrum underwent a distal gastrectomy with D2 lymphandectomy in May 2006.
  • After surgical treatment, S-1+ docetaxel combined chemotherapy was started for pEM (+) due to direct invasion to pancreas head as the first-line chemotherapy.
  • However, the local recurrence whose diameter was 24 mm at pancreas head was detected with enhanced CT in December 2006.
  • Moreover, nevertheless CPT-11+CDDP combined chemotherapy or paclitaxel monotherapy as the second or the third-line chemotherapy, respectively, the diameter of the local recurrence enlarged to 38 mm in November 2007.
  • Therefore, chemo-radiotherapy using with S-1 and CDDP was started in December 2007 and the diameter of local recurrence was reduced to 25 mm in January 2008.
  • Chemo-radiotherapy for this gastric-cancer patient with local recurrence of multiple anti-tumor drug resistance was effective and safe.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Female. Gastrectomy. Gastroscopy. Humans. Neoplasm Staging. Salvage Therapy. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106521.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


33. Kim ES: Cetuximab as a single agent or in combination with chemotherapy in lung cancer. Clin Lung Cancer; 2004 Dec;6 Suppl 2:S80-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cetuximab as a single agent or in combination with chemotherapy in lung cancer.
  • Epidermal growth factor receptor (EGFR) has become an important target in the treatment of cancer.
  • Multiple epithelial cancers have been found to overexpress the receptor including head and neck, breast, colon, lung, prostate, kidney, ovary, brain, pancreas, and bladder.
  • The inhibition of EGFR may lead to suppression of tumor proliferation and improve overall clinical outcome, as overexpression of the receptor has been associated with a poorer prognosis in patients with cancer.
  • This article will focus on the monoclonal antibody cetuximab and its applications in the treatment of non-small-cell lung cancer.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / therapy. Lung Neoplasms / therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Cetuximab. Clinical Trials as Topic. Humans. Protein Kinase Inhibitors / therapeutic use. Radiotherapy, Adjuvant. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / physiology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15638964.001).
  • [ISSN] 1525-7304
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PQX0D8J21J / Cetuximab
  • [Number-of-references] 59
  •  go-up   go-down


34. Osti MF, Costa AM, Bianciardi F, De Nicolò M, Donato V, Silecchia G, Enrici RM: Concomitant radiotherapy with protracted 5-fluorouracil infusion in locally advanced carcinoma of the pancreas: a phase II study. Tumori; 2001 Nov-Dec;87(6):398-401
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant radiotherapy with protracted 5-fluorouracil infusion in locally advanced carcinoma of the pancreas: a phase II study.
  • AIMS AND BACKGROUND: To evaluate the efficacy of combined radiation therapy and continuous infusion of 5-fluorouracil in patients with locally advanced carcinoma of the pancreas.
  • METHODS: Between January 1992 and June 1999, 31 patients with locally advanced adenocarcinoma of the pancreas were treated in our Institute.
  • In 20 patients, the tumor (65%) was located in the head of the pancreas and in 11 (35%) in the body or tail; 13 cases also showed involved nodes.
  • Radiation therapy consisted in a median dose of 63 Gy in 33-36 fractions applied to the tumor and regional lymph nodes.
  • Chemotherapy with 5-fluorouracil in continuous infusion, 250 mg/m2 daily, was administered in the first and fifth week of the radiation therapy.
  • Thereafter, 22 patients received 3-10 cycles of adjuvant chemotherapy with same doses.
  • The toxicity of the treatment was scored according to WHO criteria.
  • All patients underwent nutritional assessment at the time of radiochemotherapy.
  • At the time of the study, 2 patients (6.4%) were surgically proven disease free.
  • Tumor down-staging and resectability rates were high, together with prolonged survival and a good quality of life.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antimetabolites, Antineoplastic / therapeutic use. Fluorouracil / therapeutic use. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Radiotherapy Dosage. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11989594.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


35. Fujii M, Sato H, Ogasawara T, Ando T, Tsujii S, Nagahori J, Komatsu Y, Matsuoka A: [A case of liver metastasis of pancreatic acinar cell carcinoma treated with S-1 and intra-arterial CDDP combination therapy]. Gan To Kagaku Ryoho; 2010 Oct;37(10):1987-90
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of liver metastasis of pancreatic acinar cell carcinoma treated with S-1 and intra-arterial CDDP combination therapy].
  • A 55-year-old man underwent a pylorus-preserving pancreatoduodenectomy in August 2006 because of acinar cell carcinoma of the head of the pancreas.
  • Since abdominal CT revealed multiple liver metastases, we started systemic chemotherapy with gemcitabine (1,400 mg/body, day 1, 8, 15/q4w) in October 2006.
  • At the beginning of this treatment, it seemed to be a stable disease, but CT revealed tumor progression in January 2007.
  • Despite the change to oral chemotherapy with S-1 (100 mg/body, day 1-14/q3w), tumors were markedly enlarged in March 2007.
  • Therefore, we selected combination chemotherapy with oral S-1 and hepatic arterial infusion of CDDP (50 mg/body) as third-line.
  • After 6 months of treatment, abdominal CT revealed marked shrinkage of tumors, accompanied by a decrease in AFP level.
  • Though the patient died of hepatic failure in July 2009 (33 months after recurrence), he spent most of his time at home and worked as usual.
  • We suggest that combination chemotherapy with oral S-1 and intra-arterial CDDP can be effective treatments for pancreatic acinar cell carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Acinar Cell / drug therapy. Cisplatin / therapeutic use. Liver Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Pancreatic Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Drug Combinations. Fatal Outcome. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Recurrence. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20948270.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


36. Chu QD, Hill HC, Douglass HO Jr, Driscoll D, Smith JL, Nava HR, Gibbs JF: Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas. Ann Surg Oncol; 2002 Nov;9(9):855-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas.
  • BACKGROUND: Neuroendocrine tumors of the pancreas are rare tumors.
  • METHODS: Fifty patients with a diagnosis of neuroendocrine tumors of the pancreas were retrospectively evaluated.
  • The following factors were evaluated for disease-specific mortality: age, sex, primary tumor location, functional status, type of primary tumor treatment, presence or absence of liver metastases, timing of liver metastases occurrence, and type of liver metastases treatment.
  • Aggressive treatment of the liver metastases included surgery, chemoembolization, or intrahepatic arterial infusion chemotherapy.
  • RESULTS: Twenty-three patients (47%) had tumor located in the head of the pancreas, and 29 patients (58%) had nonfunctioning tumor.
  • Factors that had a significant favorable effect on survival included curative resection of the primary tumor, metachronous liver metastases, absence of liver metastases, and aggressive treatment of the liver metastases.
  • CONCLUSIONS: Definitive surgical resection of the primary tumor, absence of liver metastases, metachronous liver metastases, and aggressive treatment of the liver metastases were predictors of long-term survival in patients with neuroendocrine tumors of the pancreas.
  • [MeSH-minor] Adult. Aged. Female. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Male. Middle Aged. Prognosis. Retrospective Studies. Risk Assessment

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12417506.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Koizumi M, Sata N, Shimura K, Tsukahara M, Yoshizawa K, Kurihara K, Hyodo M, Yasuda Y, Nagai H: [An outpatient with unresectable pancreatic cancer treated with gemcitabine showing prolonged NC (22 months)]. Gan To Kagaku Ryoho; 2005 Dec;32(13):2133-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 76-year-old man developed jaundice and was hospitalized in January 2002.
  • A 3 cm tumor was found in the head of the pancreas by abdominal CT, and the patient underwent laparotomy.
  • The tumor was histologically diagnosed as a well-differentiated adenocarcinoma, and showed extensive invasion to the portal vein (T4NXM 0 Stage IV a).
  • On the basis of a drug sensitivity test, chemotherapy with 800 mg/m2/week gemcitabine was administered.
  • The patient showed prolonged NC without any symptoms for 22 months, although the CEA and DUPAN-2 levels gradually increased during this time and massive ascites were detected in a routine abdominal CT at 22 months postsurgery.
  • The patient died after 25 months of chemotherapy.
  • Here we report a case of unresectable pancreatic cancer treated with gemcitabine on the basis of a drug sensitivity test.
  • [MeSH-major] Adenocarcinoma / drug therapy. Ambulatory Care. Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Drug Administration Schedule. Drug Screening Assays, Antitumor. Humans. Male. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16352944.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


38. Matsumoto T, Fujiwara Y, Yamamoto N, Hayashi C, Koishi K, Kojima S, Tanaka J, Kobayashi M, Yamamura T, Miwa H, Tomita N, Sasako M: [Gastrojejunostomy for irresectable gastric cancer with pyloric stenosis-new role of surgery in the era of S-1]. Gan To Kagaku Ryoho; 2009 Apr;36(4):641-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a patient with an advanced gastric cancer complicated by pyloric stenosis who was effectively treated by S-1 mono-therapy after gastrojejunostomy.
  • Gastric roentgenography and upper gastrointestinal endoscopy showed gastric cancer(Borrmann Type 3) with pyloric stenosis.
  • He underwent laparotomy, which revealed a T4 tumor invading the pancreas head, but neither liver nor peritoneal metastasis.
  • After the operation, chemotherapy of S-1(120 mg/day, day 1-21)+cisplatin(100 mg/day, day 8)was administered.
  • After 2 courses, level of tumor marker decreased remarkably and abdominal enhanced computed tomography showed a significant size reduction of lymph nodes and that direct invasion to the pancreas was not clear any more.
  • After 4 courses of S-1(120 mg/day, day 1 approximately 28)mono-therapy as adjuvant chemotherapy, bone metastasis was confirmed by scintigram.
  • Then methotrexate+5-FU, irinotecan+cisplatin and cisplatin+paclitaxel were chosen as second-, third-and fourth-line chemotherapy, which were not effective for long.
  • In the past, gastrojejunostomy was regarded as useful palliative treatment for those with gastric outlet stenosis to ameliorate the QOL.
  • As S-1 is taking major role in the chemotherapy for advanced gastric cancer recently, usefulness of bypass surgery for such patients is highlighted even for longer survival time.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastric Bypass. Oxonic Acid / therapeutic use. Pyloric Stenosis / drug therapy. Pyloric Stenosis / surgery. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery. Tegafur / therapeutic use
  • [MeSH-minor] Biomarkers, Tumor / blood. Drug Combinations. Fatal Outcome. Gastroscopy. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19381039.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


39. Ohmura T, Umekita N, Ohkubo T, Tanaka S, Maeshiro T, Matsuo S, Miyamoto S, Inoue S, Kitamura M: [Local recurrence of pancreatic cancer successfully treated with gemcitabine]. Gan To Kagaku Ryoho; 2005 Feb;32(2):239-41
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a patient for whom systemic chemotherapy using gemcitabine was effective against local recurrence of pancreatic cancer.
  • A 58-year-old man underwent pancreatoduodenectomy for a pancreatic head cancer.
  • The diagnosis was Stage IVb poorly-differentiated tubular adenocarcinoma, scirrhous type, pT4, PL (+), P0, H0, pN2.
  • Gastroscopy and CT examination revealed a mass at the cut-end of the pancreas invading the stomach.
  • Systemic chemotherapy was performed with a regimen of gemcitabine 1,000 mg/m2/week for 2 weeks, followed by a week rest.
  • The recurrent tumor in the stomach disappeared, and the mass at the cut-end of the pancreas became small.
  • Two years after the diagnosis of recurrence, he returned to work, and his chemotherapy is being continued as an outpatient.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Pancreatic Neoplasms / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Drug Administration Schedule. Humans. Male. Middle Aged. Pancreaticoduodenectomy. Postoperative Period. Quality of Life. Remission Induction

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15751641.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


40. Snajdauf J, Rygl M, Petru O, Kalousova J, Kuklova P, Mixa V, Keil R, Hribal Z: Duodenum-sparing technique of head resection in solid pseudopapillary tumor of the pancreas in children. Eur J Pediatr Surg; 2009 Dec;19(6):354-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Duodenum-sparing technique of head resection in solid pseudopapillary tumor of the pancreas in children.
  • AIM OF STUDY: Aim of the study was to assess the complications and long-term results in children operated on for solid pseudopapillary tumor of the pancreas (SPTP) between 1993-2008 at the authors' institution with a focus on a novel duodenum-sparing technique to treat tumors of the head of the pancreas.
  • METHODS: Retrospective analysis was performed of patient data including demographics, diagnostic measures, the operative technique focusing on tumor of the head of the pancreas, complications and long-term results.
  • In 7 patients the tumor was localized in the head of the pancreas, in 4 patients in the tail, and in 2 patients both the body and tail were involved.
  • Patients with body and tail involvement underwent distal pancreatic resection.
  • In 6 patients with head involvement a duodenum-sparing resection of the head and end-to-end anastomosis of the excluded jejunal loop either to the corpus or tail of the pancreas were performed.
  • She developed a biliary fistula which closed after three weeks with endoscopic stenting.
  • One patient with head resection developed a biliary fistula which closed after two weeks of stenting.
  • One patient who underwent resection of the pancreatic head complained of recurrent abdominal pain one year postoperatively.
  • All patients are alive without tumor recurrence at 6 months to 16 years after operation.
  • CONCLUSION: SPTP is a rare pancreatic tumor with a low degree of malignancy.
  • No perioperative chemotherapy is necessary.
  • Therefore duodenal resection in cases of SPTP in the head of the gland seems too invasive and mutilating.
  • [MeSH-minor] Adolescent. Child. Female. Follow-Up Studies. Humans. Male. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) Georg Thieme Verlag KG Stuttgart-New York.
  • (PMID = 19821226.001).
  • [ISSN] 1439-359X
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


41. Hirashima Y, Kitajima K, Sugi S, Murakami K, Fujioka T, Kumamoto T: [Successful CPT-11 treatment in a patient with pancreatic cancer associated with multiple liver metastases and chronic renal failure]. Gan To Kagaku Ryoho; 2007 Jan;34(1):105-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful CPT-11 treatment in a patient with pancreatic cancer associated with multiple liver metastases and chronic renal failure].
  • A 56-year-old woman, who had been receiving treatment for chronic renal failure, was admitted to our Department because of a tumor of the pancreas head and multiple liver masses diagnosed by abdominal CT scans.
  • Gastroduodenoscopy revealed a tumor which had invaded the Vater's papilla; the lesion was histopathologically pancreatic adenocarcinoma.
  • Due to the presence of multiple metastases to the liver, we therefore performed general chemotherapy after obtaining the patient's informed consent (IC).
  • After four courses of the treatment, a CT scan revealed both the tumor of the pancreas head and the multiple liver masses to have almost completely disappeared.
  • Our clinical results indicate that CPT-11 may therefore be a strong candidate for first-line chemotherapy for the treatment of pancreatic cancer, especially in patients with renal failure.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / administration & dosage. Camptothecin / analogs & derivatives. Kidney Failure, Chronic / complications. Liver Neoplasms / secondary. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Drug Administration Schedule. Female. Humans. Middle Aged. Remission Induction


42. Honda K, Fukuhara T, Kojima Y, Tanaka H, Kushihata F, Kobayashi N: [Two cases of advanced pancreas cancer treated with GTX: combined use of gemcitabine, docetaxel and capecitabine]. Gan To Kagaku Ryoho; 2006 Dec;33(13):2089-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of advanced pancreas cancer treated with GTX: combined use of gemcitabine, docetaxel and capecitabine].
  • Two cases of advanced pancreas cancer were treated with GTX.
  • A 62-year-old man with pancreas head cancer and 2 liver metastases was treated with GEM 1,000 mg/m(2)/week at weeks 1, 2, and 3, and drug-free week 4 for 3 cycles, but was PD.
  • After 3 cycles of GTX, the liver metastases decreased in size, and thereafter tumor markers became lowest after 7 cycles.
  • A 75-year-old man with pancreas head cancer and vascular invasion has been treated with GTX.
  • The tumor reduced in size and tumor markers decreased.
  • GTX is suitable for outpatient chemotherapy with mild adverse effects.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / drug therapy. Pancreatic Neoplasms / drug therapy. Vascular Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Aged. Capecitabine. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drug Administration Schedule. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Humans. Infusions, Intravenous. Leukopenia / chemically induced. Male. Middle Aged. Neoplasm Invasiveness. Taxoids / administration & dosage

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197760.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


43. Cella D, Paul D, Yount S, Winn R, Chang CH, Banik D, Weeks J: What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Invest; 2003;21(4):526-35
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We derived a set of brief, clinically relevant symptom indices for assessing symptomatic response to chemotherapy for advanced bladder, brain, breast, colorectal, head and neck, hepatobiliary/pancreas, lung, ovarian, and prostate cancers.
  • Questions were extracted from a multidimensional cancer quality of life (QOL) measurement system, the Functional Assessment of Cancer Therapy (FACT).
  • In a two-step procedure, each expert narrowed the list to no more than five of the very most important to attend to when assessing the value of drug treatment for advanced disease.
  • Fatigue, pain, nausea, weight loss, worry about worsening condition, and contentment with current QOL were consistently selected by experts as priority symptoms across tumor sites.
  • These nine tumor-specific symptom indices indicate the most important clinician-rated targets of chemotherapy for many advanced cancers.
  • [MeSH-major] Cancer Care Facilities. Community Networks. Neoplasms / complications. Neoplasms / therapy. Practice Guidelines as Topic. Quality of Life

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Cancer Invest. 2003;21(4):663-4 [14533454.001]
  • (PMID = 14533442.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Comment; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


44. Obuchi T, Sasaki A, Shimooki O, Minakawa Y, Abe T, Nitta H, Otsuka K, Koeda K, Ikeda K, Wakabayashi G: [Local recurrence after surgical resection of pancreatic cancer effectively treated with combined chemoradiotherapy]. Gan To Kagaku Ryoho; 2009 Jun;36(6):991-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a patient for whom systemic chemotherapy using gemcitabine was effective against local recurrence of pancreatic cancer.
  • A 59-year-old man underwent pancreatoduodenectomy for pancreatic head cancer.
  • The diagnosis was moderately-differentiated tubular adenocarcinoma(tubular type, pT2, pN0, fM0, fStage II ).
  • Ten months after surgery, the patient had a CT examination which revealed a mass at the cut-end of the pancreas.
  • Chemotherapy with GEM(1,000 mg/m2)was administered intravenously on days 1, 8, and 15.
  • The patient received 8 courses of chemotherapy by GEM, and the regimen was changed to every two weeks because of the adverse event, leucopenia(grade 2)and thrombocytopenia( grade 2).
  • Twenty-one months after chemotherapy, CT examination revealed regrowth at the same location at the cut-end of the pancreas, and so radiotherapy was performed at a total 63 Gy.
  • The patient had been receiving systemic chemotherapy as an outpatient for 48 months without deterioration of quality of life.
  • Our experience suggests that this chemotherapy is simple and possible to continue safely on an ambulatory basis while maintaining quality of life.
  • [MeSH-major] Adenocarcinoma / therapy. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biomarkers, Tumor / blood. CA-19-9 Antigen / blood. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drug Administration Schedule. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Pancreaticoduodenectomy. Tegafur / administration & dosage. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542722.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0W860991D6 / Deoxycytidine; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; B76N6SBZ8R / gemcitabine; 1-UFT protocol
  •  go-up   go-down


45. Weichselbaum RR, Kufe D: Translation of the radio- and chemo-inducible TNFerade vector to the treatment of human cancers. Cancer Gene Ther; 2009 Aug;16(8):609-19
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translation of the radio- and chemo-inducible TNFerade vector to the treatment of human cancers.
  • Radiotherapy is a widely used treatment for localized malignancies that is often delivered in combination with cytotoxic chemotherapeutic agents.
  • The concept that treatment of localized tumors can be improved with a radio- and chemo-inducible gene therapy strategy has been investigated in the laboratory and now translated to the clinic.
  • The TNFerade (Ad.Egr-TNF11D) adenoviral vector was engineered by inserting radio- and chemo-inducible elements from the Egr-1 promoter upstream to a cDNA encoding tumor necrosis factor-alpha (TNF-alpha).
  • Transduction of tumor cells with TNFerade and then treatment with radiation or chemotherapy is associated with spatial and temporal control of TNF-alpha secretion and enhanced antitumor activity.
  • TNFerade has been evaluated in trials for patients with sarcomas, melanomas and cancers of the pancreas, esophagus, rectum and head and neck.
  • If the ongoing phase III trial for pancreatic cancer is successful, TNFerade will likely become the first gene therapy approved for cancer in the United States.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Genetic Therapy / methods. Neoplasms / therapy. Radiotherapy. Tumor Necrosis Factor-alpha / biosynthesis
  • [MeSH-minor] Drug Delivery Systems / methods. Genetic Vectors / metabolism. Humans. Radiation, Ionizing

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19444302.001).
  • [ISSN] 1476-5500
  • [Journal-full-title] Cancer gene therapy
  • [ISO-abbreviation] Cancer Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


46. Yang F, Jin C, Long J, Yu XJ, Xu J, Di Y, Li J, Fu de L, Ni QX: Solid pseudopapillary tumor of the pancreas: a case series of 26 consecutive patients. Am J Surg; 2009 Aug;198(2):210-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid pseudopapillary tumor of the pancreas: a case series of 26 consecutive patients.
  • OBJECTIVE: Solid pseudopapillary tumor (SPT) of the pancreas, which predominantly affects young women, is a relatively indolent entity with favorable prognosis.
  • Clinicopathologic factors were compared between benign and malignant cases to determine what features of the tumor could suggest malignant potential.
  • The neoplasm was localized in the pancreatic head/neck in 14 patients and in the body/tail in 12 patients.
  • All of the tumors-including 8 pancreaticoduodenectomies, 10 distal pancreatectomies, 6 local resections, 1 total pancreatectomy, and 1 central pancreatectomy-were resected successfully.
  • No patient received chemotherapy or radiotherapy after surgery.
  • One of the 2 patients with malignant SPT, in whom Ki-67 immunoreactivity was >25%, developed local recurrence with liver metastasis 4 months and died 6 months after surgery.
  • CONCLUSIONS: SPT is a rare neoplasm with low malignant potential.
  • Characteristic computed axial tomography and magnetic resonance imaging scans combined with age and sex profile should be sufficient for the decision to operate.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19268906.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Choi SH, Kim SM, Oh JT, Park JY, Seo JM, Lee SK: Solid pseudopapillary tumor of the pancreas: a multicenter study of 23 pediatric cases. J Pediatr Surg; 2006 Dec;41(12):1992-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid pseudopapillary tumor of the pancreas: a multicenter study of 23 pediatric cases.
  • BACKGROUND/PURPOSE: Solid pseudopapillary tumor (SPT) is a very rare form of childhood pancreatic tumor.
  • This study was intended to analyze the clinicopathologic characteristics of this tumor in childhood.
  • Tumors were located in the pancreatic head (30%), body (13%), tail (44%), and both body and tail (13%).
  • Operative procedures performed were pylorus-preserving pancreaticoduodenectomy (n = 6, 26.1%), distal pancreatectomy (n = 7, 30.4%), distal pancreatectomy with splenectomy (n = 7, 30.4%).
  • One patient showed multiple liver metastasis 3 months after the initial operation and required adjuvant chemotherapy.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17161189.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


48. Gambacorta MA, Macchia G, Deodato F, Murino P, Barba MC, Manfrida S: When can a drug be considered synergic with radiotherapy? Rays; 2004 Jul-Sep;29(3):291-9
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] When can a drug be considered synergic with radiotherapy?
  • The combination of radiotherapy with chemotherapy is now considered the standard treatment for a number of tumors.
  • However frequently, within radiotherapy as well as medical oncology, considerable skepticism has been expressed about the real impact of this therapeutic modality, in spite of the improvement in terms of outcome seen in numerous trials concerning head and neck, lung, esophageal cancer and tumors of the anal canal, the uterine cervix and pancreas.
  • As for the preclinical evaluation different methods should be concomitantly used to analyze the pharmacokinetics and mechanism of action; the method of tumor growth delay should be used especially in neoadjuvant clinical settings; the method of tumor control should be used when chemoradiation is aimed at the local cure of the patient independently of subsequent surgery.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Drug Therapy / standards. Neoplasms / drug therapy. Neoplasms / radiotherapy
  • [MeSH-minor] Clinical Trials as Topic. Combined Modality Therapy. Humans. Outcome Assessment (Health Care). Research Design

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15603301.001).
  • [ISSN] 0390-7740
  • [Journal-full-title] Rays
  • [ISO-abbreviation] Rays
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 24
  •  go-up   go-down


49. Fernández JA, Robles R, Marín C, Hernández Q, Sánchez Bueno F, Ramírez P, Rodríguez JM, Luján JA, Navalón JC, Parrilla P: Role of liver transplantation in the management of metastatic neuroendocrine tumors. Transplant Proc; 2003 Aug;35(5):1832-3
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: In the majority of patients transplanted for unresectable liver metastases, long-term results are disappointing because of early tumor recurrence.
  • The primary tumors were located in the pancreas (n=4) and the small bowel (n=1).
  • The management of primary tumors was sequential in three patients with the tumor being resected before LT (one Whipple procedure and two left pancreatectomies).
  • All patients were treated with chemotherapy.
  • RESULTS: Two patients developed recurrent disease succumbing at 15 months (nonfunctioning NE pancreatic head tumor) and 17 months (carcinoid of the pancreatic tail) post-LT.
  • [MeSH-minor] Adult. Fatal Outcome. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12962813.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Beger HG, Rau B, Gansauge F, Poch B, Link KH: Treatment of pancreatic cancer: challenge of the facts. World J Surg; 2003 Oct;27(10):1075-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of pancreatic cancer: challenge of the facts.
  • Adenocarcinoma of the pancreas is associated with the worst survival of any form of gastrointestinal malignancy.
  • In spite of the progress in surgical treatment, resulting in increasing resection rates and a decrease in treatment-related morbidity and mortality, the true figures of cure are even today below 3%.
  • The dissemination of pancreatic cancer behind the local tissue compartments restricts the short-term (< 3 years) and long-term outcome for patients who have undergone resection.
  • Major contributions of surgery to improved treatment results are the reduction of surgical morbidity--e.g., early postoperative local and systemic complications--and a decrease of hospital mortality below 3%-5%.
  • In most recently published prospective trials, R(0) resection has been reported to result in an increase in short-term survival beyond that recorded for patients with residual tumor.
  • In many published R(0) series, standard tissue resection of pancreatic head cancer with the Kausch-Whipple procedure failed to include remote cancer cell-positive tissues in the operative specimen; e.g., N(2)-lymph nodes, nerve plexus, and perivascular extrapancreatic and retropancreatic tissues were not excised.
  • The assessment of clinical benefit from surgical or medical cancer treatment should therefore be based on several end points, not only on actuarial survival.
  • In reporting pancreatic cancer treatment trial results after oncological resections, more convincing primary end points to evaluate treatment efficacy are median survival (in months), actual survival at 1-5 years, and progression-free survival (in months).
  • In series with multimodality treatment, clinical benefit response as well as quality of life measurements using the EORTC Quality of Life index C30 (QLQ-C30) are of importance in evaluating survival data.
  • Adjuvant treatment improves survival after oncological resection; however, the short-term and long-term benefit after adjuvant chemotherapy in R(0) as well as in R(1)-(2) resected patients has not yet been underscored by data from controlled clinical trials.
  • The survival benefit (median survival time) of adjuvant chemotherapy or radiochemotherapy has been demonstrated to be 6-10 months.
  • Therefore, after oncological resection of pancreatic cancer each patient should be offered adjuvant treatment.
  • A neoadjuvant treatment protocol for pancreatic cancer, however, has not been established.
  • [MeSH-major] Pancreatic Neoplasms / therapy

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Gastroenterol. 2002 Aug;35(2):180-4 [12172365.001]
  • [Cites] Ann Surg. 1998 Jun;227(6):821-31 [9637545.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):508-17 [9790340.001]
  • [Cites] Hepatogastroenterology. 1997 Nov-Dec;44(18):1528-35 [9427017.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Jun 15;26(3):483-9 [8390422.001]
  • [Cites] Am J Surg. 1991 Jan;161(1):120-4; discussion 124-5 [1987845.001]
  • [Cites] Pancreas. 1997 Aug;15(2):154-9 [9260200.001]
  • [Cites] Surgery. 1995 Jan;117(1):50-5 [7809836.001]
  • [Cites] Br J Surg. 1998 Apr;85(4):498-501 [9607531.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2001;8(5):441-8 [11702254.001]
  • [Cites] Cancer. 1994 Jun 15;73(12):2930-5 [8199990.001]
  • [Cites] Ann Surg. 2002 Sep;236(3):355-66; discussion 366-8 [12192322.001]
  • [Cites] World J Surg. 1995 Jul-Aug;19(4):653-9; discussion 660 [7676716.001]
  • [Cites] J Am Coll Surg. 1999 Jul;189(1):46-56 [10401740.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(4):450-4 [9931396.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(3):242-50 [9880770.001]
  • [Cites] Lancet. 2001 Nov 10;358(9293):1576-85 [11716884.001]
  • [Cites] Ann Surg. 1997 Jul;226(1):66-9 [9242339.001]
  • [Cites] Dig Surg. 1999;16(4):337-45 [10449979.001]
  • [Cites] Int J Cancer. 1996 Aug 22;69(4):278-82 [8797868.001]
  • [Cites] Baillieres Clin Gastroenterol. 1990 Dec;4(4):985-93 [2078795.001]
  • [Cites] Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4 [10615932.001]
  • [Cites] Am J Surg. 1996 Jan;171(1):170-4; discussion 174-5 [8554135.001]
  • [Cites] Br J Surg. 1995 Dec;82(12):1686-91 [8548242.001]
  • [Cites] Int J Pancreatol. 1991 Oct;10(2):105-11 [1748826.001]
  • [Cites] Acta Pathol Jpn. 1992 Feb;42(2):99-103 [1314008.001]
  • [Cites] Ann Surg. 1990 Apr;211(4):447-58 [2322039.001]
  • [Cites] Hepatogastroenterology. 1997 Sep-Oct;44(17):1463-8 [9356873.001]
  • [Cites] Br J Surg. 1997 Oct;84(10 ):1370-6 [9361591.001]
  • [Cites] Cancer. 2000 Jul 15;89(2):314-27 [10918161.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):43-9 [7826160.001]
  • [Cites] Br J Surg. 1996 May;83(5):625-31 [8689203.001]
  • [Cites] Am J Surg. 2000 May;179(5):367-71 [10930481.001]
  • [Cites] Ann Surg. 1995 Nov;222(5):638-45 [7487211.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):56-61 [2354408.001]
  • [Cites] Arch Surg. 2000 Dec;135(12):1450-5 [11115351.001]
  • [Cites] Eur J Surg Oncol. 1991 Apr;17(2):167-72 [2015921.001]
  • [Cites] Ann Surg. 1997 May;225(5):621-33; discussion 633-6 [9193189.001]
  • [Cites] Cancer. 1998 Oct 1;83(7):1328-34 [9762933.001]
  • [Cites] Am J Surg. 1994 Oct;168(4):361-4 [7943597.001]
  • [Cites] Br J Surg. 1995 Jan;82(1):111-5 [7881926.001]
  • [Cites] Arch Surg. 1993 May;128(5):559-64 [8098206.001]
  • [Cites] Jpn J Cancer Res. 1995 Jul;86(7):626-30 [7559078.001]
  • [Cites] Ann Surg. 1992 Mar;215(3):231-6 [1543394.001]
  • [Cites] J Gastrointest Surg. 2003 Jan;7(1):1-9; discussion 9-11 [12559179.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):928-37 [9060530.001]
  • [Cites] Br J Surg. 1994 Nov;81(11):1642-6 [7827892.001]
  • [Cites] Hepatogastroenterology. 1996 Mar-Apr;43(8):320-5 [8714223.001]
  • [Cites] Int J Pancreatol. 1991 Oct;10(2):113-9 [1660909.001]
  • [Cites] Ann Surg. 1968 Oct;168(4):629-40 [5680953.001]
  • [Cites] Surgery. 1997 Mar;121(3):244-9 [9068665.001]
  • [Cites] Ann Surg. 2000 Dec;232(6):786-95 [11088073.001]
  • [Cites] Pancreas. 1997 Nov;15(4):374-8 [9361091.001]
  • [Cites] Cancer. 1987 Nov 1;60(9):2284-303 [3326653.001]
  • [Cites] Am J Surg. 1993 Jan;165(1):68-72; discussion 72-3 [8380315.001]
  • [Cites] Cancer. 1993 Oct 1;72 (7):2118-23 [8104092.001]
  • [Cites] Cancer. 1987 Jun 15;59(12):2006-10 [3567862.001]
  • [Cites] Cancer. 1999 Mar 15;85(6):1261-8 [10189130.001]
  • [Cites] Pancreas. 1996 May;12(4):357-61 [8740402.001]
  • [Cites] Int J Pancreatol. 1988 Dec;3(6):491-6 [3221109.001]
  • [Cites] Am J Gastroenterol. 1985 Jun;80(6):459-62 [4003374.001]
  • [Cites] Surgery. 1999 Mar;125(3):250-6 [10076608.001]
  • [Cites] World J Surg. 1999 Sep;23(9):946-9 [10449825.001]
  • [Cites] World J Surg. 1993 Jan-Feb;17(1):122-6; discussion 126-7 [8383381.001]
  • [Cites] J Gastrointest Surg. 1997 Sep-Oct;1(5):446-53 [9834377.001]
  • [Cites] Cancer. 1992 Feb 15;69(4):930-5 [1735083.001]
  • [Cites] Hepatogastroenterology. 1993 Aug;40(4):384-7 [8406311.001]
  • [Cites] Cancer. 1996 Dec 15;78(12):2485-91 [8952555.001]
  • [Cites] Int J Cancer. 1994 May 1;57(3):330-5 [8168992.001]
  • [Cites] Am J Surg. 1996 Sep;172(3):297-8 [8862089.001]
  • [Cites] Ann Surg. 1986 Jan;203(1):77-81 [3942423.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):59-66 [7826162.001]
  • [Cites] Br J Surg. 1994 Aug;81(8):1190-3 [7953357.001]
  • [Cites] Surgery. 1991 Apr;109(4):481-7 [1848949.001]
  • [Cites] Arch Surg. 1985 Aug;120(8):899-903 [4015380.001]
  • [Cites] World J Surg. 2001 Aug;25(8):1002-5 [11571964.001]
  • [Cites] Ann Surg. 1996 Sep;224(3):342-7; discussion 347-9 [8813262.001]
  • (PMID = 12925907.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Editorial
  • [Publication-country] United States
  •  go-up   go-down


51. Caricato M, Borzomati D, Ausania F, Garberini A, Rabitti C, Tonini G, Coppola R: Cerebellar metastasis from pancreatic adenocarcinoma. A case report. Pancreatology; 2006;6(4):306-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two years earlier the patient had undergone a pancreaticoduodenectomy for an adenocarcinoma of the head of the pancreas with a lymph node metastasis.
  • After complete surgical removal of the tumor, he underwent adjuvant chemoradiation.
  • Clinical evaluation revealed an intracranial tumor without signs of pancreatic recurrence.
  • The tumor was surgically removed.
  • One year later the patient developed multiple brain metastases and he is currently undergoing gemcitabine-based chemotherapy.
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Humans. Male. Pancreaticoduodenectomy. Recurrence. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 S. Karger AG, Basel and IAP.
  • (PMID = 16636605.001).
  • [ISSN] 1424-3903
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


52. Smith V, Sausville EA, Camalier RF, Fiebig HH, Burger AM: Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. Cancer Chemother Pharmacol; 2005 Aug;56(2):126-37
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The heat shock protein Hsp90 is a potential target for drug discovery of novel anticancer agents.
  • 17DMAG was found to be more potent than 17AAG in a panel of 64 different patient-derived tumor explants studied in vitro in the clonogenic assay.
  • The tumor types that responded best included mammary cancers (six of eight), head and neck cancers (two of two), sarcomas (four of four), pancreas carcinoma (two of three), colon tumors (four of eight for 17AAG and six of eight for 17DMAG), and melanoma (two of seven).
  • Using three permanent human melanoma cell lines with differing sensitivities to 17AAG and 17DMAG (MEXF 276L, MEXF 462NL and MEXF 514L), we found that Hsp90 protein was reduced following treatment at a concentration associated with total growth inhibition.
  • Levels of known Hsp90 client proteins such as phosphorylated AKT followed by AKT, cyclin D1 preceding cdk4, and craf-1 declined as a result of drug treatment in all three melanoma cell lines.
  • However, the duration of drug exposure needed to achieve these effects was variable.
  • [MeSH-major] Melanoma / drug therapy. Neoplasms / pathology. Quinones / pharmacology. Rifabutin / analogs & derivatives. Rifabutin / pharmacology. Skin Neoplasms / drug therapy
  • [MeSH-minor] Animals. Base Sequence. Benzoquinones. Drug Screening Assays, Antitumor. HSP90 Heat-Shock Proteins / drug effects. Humans. Lactams, Macrocyclic. Mice. Mice, Nude. Molecular Sequence Data. Protein-Serine-Threonine Kinases. Transplantation, Heterologous. Tumor Cells, Cultured


53. Nakamura Y, Tajiri T, Uchida E, Arima Y, Aimoto T, Katsuno A, Naito Z: Changes to levels of serum neuron-specific enolase in a patient with small cell carcinoma of the pancreas. J Hepatobiliary Pancreat Surg; 2005;12(1):93-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes to levels of serum neuron-specific enolase in a patient with small cell carcinoma of the pancreas.
  • Small cell carcinoma (SCC) of the pancreas is a rare disease, with an extremely poor prognosis; only 24 cases have been reported in the literature.
  • However, as some patients have been successfully treated with combination chemotherapy, it is important to obtain both a definite diagnosis and a precise evaluation of the effect of the treatment.
  • A 69-year-old woman presented with an abdominal tumor and pain.
  • She had been observed for sensory neuropathy and swelling of the pancreatic head by the referring doctor over the previous 9 months.
  • The patient was diagnosed with SCC of the pancreas after surgery and had two courses of combination chemotherapy (cisplatin and etoposide).
  • Initially, the tumor disappeared completely on computed tomography (CT) scans, but she died of disease recurrence 3 months after completing the chemotherapy.
  • NSE levels had already increased above the upper limit of normal 8 months before the patient's admission to our hospital, and levels changed concurrently not only with tumor growth but also subsequently with remission and then relapse of the disease after treatment.
  • These results indicate that NSE is a good marker, both as a diagnostic indicator for SCC of the pancreas and as a means of evaluating response to treatment.
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Female. Humans

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15754108.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


54. Kim ES, Khuri FR, Herbst RS: Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol; 2001 Nov;13(6):506-13
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment of solid tumors despite improved techniques in detection, surgery, radiation therapy, and chemotherapy remains difficult.
  • Many epithelial cancers have been found to overexpress the receptor to epidermal growth factor (EGFR), including head and neck, breast, colon, lung, prostate, kidney, ovary, brain, pancreas, and bladder.
  • Because overexpression of EGFR has been associated with an overall poor prognosis in patients with cancer, a number of strategies to block or downregulate EGFR have been developed to inhibit tumor proliferation and improve overall clinical outcome.
  • Ultimately, IMC-C225 may prove to become a valuable contributor in the treatment of cancer.
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Cetuximab. Clinical Trials as Topic. Down-Regulation. Humans. Ligands. Neoplasms / drug therapy. Neoplasms / immunology. Prognosis. Protein-Tyrosine Kinases / antagonists & inhibitors. Protein-Tyrosine Kinases / metabolism

  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11673692.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Ligands; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PQX0D8J21J / Cetuximab
  • [Number-of-references] 72
  •  go-up   go-down


55. Uesato M, Nabeya Y, Miyazaki S, Aoki T, Akai T, Shuto K, Tanizawa T, Miyazaki M, Matsubara H: Postoperative recurrence of an IPMN of the pancreas with a fistula to the stomach. World J Gastrointest Endosc; 2010 Oct 16;2(10):349-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative recurrence of an IPMN of the pancreas with a fistula to the stomach.
  • We report on a case of a 74 year old man who was diagnosed with a recurrence of non-invasive carcinoma of intraductal papillary mucinous neoplasm (non-invasive IPMN) by postoperative gastroscopy (GS).
  • A pylorus preserving pancreatico duodenectomy for IPMN in the pancreatic head was performed.
  • At first, the local recurrence of the tumor around the superior mesenteric artery circumference was diagnosed and disappeared with gemcitabine.
  • The lesion had a central dip and a fistula common to the pancreas was confirmed on fisterography.
  • We diagnosed a recurrence of IPMN and administered chemotherapy again.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160585.001).
  • [ISSN] 1948-5190
  • [Journal-full-title] World journal of gastrointestinal endoscopy
  • [ISO-abbreviation] World J Gastrointest Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2999103
  • [Keywords] NOTNLM ; Endoscopy / Fistula / Intraductal papillary mucinous neoplasm / Recurrence / Stomach
  •  go-up   go-down


56. Nio K, Shimakami T, Yamashita T, Kagaya T, Sakai Y, Yamashita T, Mizukoshi E, Sakai A, Nakamoto Y, Honda M, Kaneko S, Kitagawa H, Kayahara M, Ohta T, Zen Y: [Two cases of a nonfunctioning pancreatic endocrine tumor found on a medical checkup]. Nihon Shokakibyo Gakkai Zasshi; 2009 Apr;106(4):560-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of a nonfunctioning pancreatic endocrine tumor found on a medical checkup].
  • Case 1) A 35-year-old man was admitted to our hospital for detailed examination of a 50-mm pancreas head tumor with surrounding lymph node swelling detected on medical checkup images.
  • Ultrasound-guided lymph node biopsy specimens gave a diagnosis of a nonfunctioning pancreatic neuroendocrine cancer, and adjuvant systemic chemotherapy was given after surgical resection of the tumor.
  • Case 2) A 52-year-old man was admitted to our hospital for detailed examination of an 18-mm pancreas head tumor detected by medical checkup FDG-PET images.
  • Imaging tests gave a diagnosis of a nonfunctioning pancreatic neuroendocrine tumor.
  • He underwent surgical resection, and the tumor was diagnosed as benign pathologically.
  • Increased prevalence of FDG-PET checkup may increase the diagnosis of pancreatic neuroendocrine tumor in asymptomatic subjects.
  • [MeSH-major] Pancreatic Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19346726.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 27
  •  go-up   go-down


57. Lin H, Li SD, Hu XG, Li ZS: Primary pancreatic lymphoma: report of six cases. World J Gastroenterol; 2006 Aug 21;12(31):5064-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A retrospective review of the clinical presentation, imaging characteristics and pathological features of PPL patients were presented, as well as their diagnosis and treatment, in combination with literature review.
  • RESULTS: Histological diagnosis was made in four patients by surgery and in two patients by EUS-FNA.
  • One of the patients developed acute pancreatitis.
  • Abdominal CT scan showed that three of the six tumors were located in the head of pancreas, two in the body and tail, and one throughout the pancreas.
  • Diameter of the tumors in the pancreas in four cases was more than 6 cm, with homogeneous density and unclear borders.
  • Enhanced CT scan showed that only the tumor edges were slightly enhanced.
  • The pancreatic duct was irregularly narrowed in two cases whose tumors were located in the pancreatic head and body, in which endoscopic retrograde cholangiopancreatography (ERCP) showed that the proximal segment was slightly dilated.
  • The diagnosis of B-cell non-Hodgkin's lymphoma was made in all patients histopathologically.
  • All six patients underwent systemic chemotherapy, one of whom was also treated with gamma radiometry.
  • One patient died two weeks after diagnosis, two patients lost follow-up, two patients who received chemotherapy survived 49 and 37 mo, and the remaining patient is still alive 21 mo, after diagnosis and treatment.
  • EUS-guided fine-needle aspiration (EUS-FNA) of the pancreas requires experienced cytopathologists as well as advanced immunohistochemical assays to obtain a final diagnosis on a small amount of tissue.
  • Surgery and adjuvant chemotherapy or radiotherapy can produce fairly good outcomes.
  • [MeSH-major] Lymphoma / diagnosis. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 2000 Mar;174(3):671-5 [10701607.001]
  • [Cites] JOP. 2006;7(3):262-73 [16685107.001]
  • [Cites] Gastrointest Endosc. 2001 Apr;53(4):470-4 [11275888.001]
  • [Cites] Gastrointest Endosc. 2001 Apr;53(4):485-91 [11275890.001]
  • [Cites] Oncology. 2001;60(4):322-9 [11408800.001]
  • [Cites] Radiology. 2001 Jul;220(1):97-102 [11425979.001]
  • [Cites] Gastrointest Endosc. 2002 Aug;56(2):218-24 [12145600.001]
  • [Cites] Surg Endosc. 2002 Jul;16(7):1107-8 [11984658.001]
  • [Cites] Am J Clin Pathol. 2004 Jun;121(6):898-903 [15198364.001]
  • [Cites] Cancer. 1972 Jan;29(1):252-60 [5007387.001]
  • [Cites] Am J Surg. 1979 Dec;138(6):929-33 [92204.001]
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] Am Surg. 1993 Aug;59(8):513-8 [8338282.001]
  • [Cites] Pancreas. 1994 Sep;9(5):662-7 [7809023.001]
  • [Cites] Eur Radiol. 1997;7(6):875-86 [9228103.001]
  • [Cites] Ann Oncol. 1997 Aug;8(8):727-37 [9332679.001]
  • [Cites] Surgery. 1998 Apr;123(4):382-90 [9551063.001]
  • [Cites] J Clin Pathol. 1998 Jan;51(1):80-2 [9577380.001]
  • [Cites] Am J Gastroenterol. 1998 Aug;93(8):1329-33 [9707060.001]
  • [Cites] Cancer. 2004 Oct 25;102(5):315-21 [15386314.001]
  • [Cites] Haematologica. 2005 Feb;90(2):ECR09 [15713583.001]
  • [Cites] Surgery. 2001 Mar;129(3):380-3 [11231470.001]
  • (PMID = 16937508.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4087415
  •  go-up   go-down


58. Lee MK, Jeon SW, Lee YD, Seo HE, Cho CM, Kim SG, Yoon YK: A case of primary pancreatic non-Hodgkin's lymphoma. Korean J Intern Med; 2006 Jun;21(2):123-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a rare presentation of diffuse large B cell lymphoma, appearing as a primary tumor of the pancreas.
  • Computed tomography of the abdomen showed a well defined mass located at the head of the pancreas.
  • A frozen section of pancreas, during laparotomy, revealed lymphoma.
  • The patient received 6 cycles of chemotherapy and is currently in complete remission.
  • This case underscores the importance of differentiating primary lymphoma from the more common adenocarcinoma of the pancreas as treatment and prognosis differ significantly.
  • Primary pancreatic lymphoma should be considered in the differential diagnosis of pancreatic tumors and an attempt to obtain a tissue diagnosis is always necessary before proceeding to radical surgery, especially on young patients.
  • [MeSH-major] Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Pancreatic Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 2000 Mar;190(3):319-30 [10703858.001]
  • [Cites] Med Oncol. 2000 Aug;17(3):237-47 [10962538.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(6):610-3 [11180896.001]
  • [Cites] Hepatogastroenterology. 2004 Jan-Feb;51(55):259-61 [15011880.001]
  • [Cites] Acta Cytol. 1998 May-Jun;42(3):834-6 [9622727.001]
  • [Cites] Radiology. 1993 Apr;187(1):99-104 [8451443.001]
  • [Cites] Pancreas. 1994 Sep;9(5):662-7 [7809023.001]
  • [Cites] J Clin Gastroenterol. 1996 Sep;23(2):109-12 [8877636.001]
  • [Cites] Surgery. 1998 Apr;123(4):382-90 [9551063.001]
  • [Cites] Ann Surg. 1989 Jan;209(1):25-30 [2910212.001]
  • (PMID = 16913443.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3890735
  •  go-up   go-down


59. Kaiho T, Tanaka T, Tsuchiya S, Yanagisawa S, Takeuchi O, Miura M, Saigusa N, Hayasaka A, Matsuzaki O, Miyazaki M: A case of small cell carcinoma of the common bile duct. Hepatogastroenterology; 2005 Mar-Apr;52(62):363-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography and ultrasonography showed a mass near the pancreas head and dilatation of the intrahepatic bile ducts.
  • Upon laparotomy, a tumor was found to be located in the middle common bile duct.
  • The main trunk of the portal vein and the right hepatic artery were resected concomitantly because of tumor involvement.
  • The patient then underwent two postoperative courses of systemic chemotherapy.
  • Nevertheless, she died of cancer recurrence eight months after the operation, which showed that the tumor had a highly lethal nature, with rapid and widespread dissemination.
  • Further therapeutic trials are needed to improve survival in such cases.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Carcinoma, Small Cell / diagnosis. Common Bile Duct
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Cholangiopancreatography, Magnetic Resonance. Fatal Outcome. Female. Humans. Neoplasm Recurrence, Local. Pancreaticoduodenectomy / methods. Tomography, X-Ray Computed. Ultrasonography

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15816436.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


60. Dokmak S, Cabral C, Couvelard A, Aussilhou B, Belghiti J, Sauvanet A: Pancreatic metastasis from nephroblastoma: an unusual entity. JOP; 2009;10(4):396-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When metastatic disease is limited to the pancreas, pancreatic resection is the optimal treatment.
  • Imaging studies revealed one 2 cm nodule in the pancreatic head with upstream dilatation of the Wirsung duct.
  • Surgical resection was performed without preoperative chemotherapy because the patient was symptomatic and had already received numerous chemotherapy protocols.
  • After resection, the patient received adjuvant high dose chemotherapy with autologous hematopoietic stem-cell support.
  • A nephroblastoma, like clear cell renal carcinoma, can be considered a possible etiology of pancreatic metastasis from a primary renal tumor.
  • [MeSH-major] Kidney Neoplasms / pathology. Pancreatic Neoplasms / secondary. Wilms Tumor / pathology
  • [MeSH-minor] Combined Modality Therapy. Drug Therapy / methods. Humans. Male. Pancreaticoduodenectomy / methods. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19581742.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


66. Juergens R, Brahmer J: Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how? Curr Oncol Rep; 2007 Jul;9(4):255-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Compounds aimed at targeting this pathway have been approved for use by the US Food and Drug Administration for lung, head and neck, pancreas, and colorectal carcinomas.
  • This article reviews the data on agents that exploit tumor dependency on epidermal growth factor receptor cascade and describes the knowledge on how to discern the appropriate patient population for receiving these agents.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Receptor, Epidermal Growth Factor / immunology
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cetuximab. Clinical Trials as Topic. Erlotinib Hydrochloride. Female. Humans. Male. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lung Cancer. 2006 Nov;54(2):193-9 [16996166.001]
  • [Cites] J Clin Oncol. 2006 Apr 20;24(12):1807-13 [16622257.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):777-84 [14990632.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):5892-9 [16043829.001]
  • [Cites] Oncogene. 2000 Dec 27;19(56):6550-65 [11426640.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9089-96 [16301597.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2240-50 [11980995.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):447-52 [17082511.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5034-42 [17075123.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2237-46 [12748244.001]
  • [Cites] JAMA. 2003 Oct 22;290(16):2149-58 [14570950.001]
  • [Cites] Chest. 2005 Jul;128(1):370-81 [16002959.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4292-302 [12409327.001]
  • [Cites] BMC Cancer. 2006 May 08;6:122 [16681848.001]
  • [Cites] Curr Opin Obstet Gynecol. 2007 Feb;19(1):56-62 [17218853.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3798-807 [12953099.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2544-55 [15753462.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):133-44 [16014883.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1589-97 [15117980.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2095-103 [10811675.001]
  • [Cites] Drugs Today (Barc). 2003;39 Suppl C:61-80 [14988746.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3267-79 [11432895.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):785-94 [14990633.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2556-68 [15767641.001]
  • [Cites] Invest New Drugs. 2005 Dec;23(6):513-22 [16267627.001]
  • [Cites] Cancer Res. 1993 Sep 15;53(18):4322-8 [8364927.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3238-47 [15310767.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 [15329413.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8786-93 [16246975.001]
  • [Cites] Environ Health Perspect. 1995 Nov;103 Suppl 8:143-8 [8741774.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):760-6 [17228019.001]
  • [Cites] Endocr Relat Cancer. 2003 Mar;10(1):1-21 [12653668.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8081-92 [16204011.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6838-45 [15998906.001]
  • [Cites] Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37 [16257339.001]
  • [Cites] Clin Lung Cancer. 2006 Jul;8(1):30-8 [16870043.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5253-8 [17114658.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):123-32 [16014882.001]
  • [Cites] Br J Cancer. 2006 Jun 5;94(11):1599-603 [16670714.001]
  • [Cites] Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232 [7612182.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6049-55 [17062680.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3815-25 [12228201.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • (PMID = 17588349.001).
  • [ISSN] 1523-3790
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PQX0D8J21J / Cetuximab; S65743JHBS / gefitinib
  • [Number-of-references] 50
  •  go-up   go-down


67. Suzuki K, Miyamoto M, Miyamoto T, Hirata K: Insulinoma with early-morning abnormal behavior. Intern Med; 2007;46(7):405-8
Hazardous Substances Data Bank. GLUCOSE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a 65-year-old man with insulinoma who initially developed stereotypical behaviors and then progressed to more complex behaviors occurring early in the morning.
  • Insulinoma was diagnosed based on fasting blood glucose level of 15 mg/dl, high fasting immunoreactive insulin/blood glucose ratio (more than 0.3), and a tumor in the pancreas head by abdominal CT.
  • [MeSH-major] Behavioral Symptoms / etiology. Hypoglycemia / diagnosis. Hypoglycemia / psychology. Insulinoma / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Behavior. Drug Therapy, Combination. Follow-Up Studies. Glucose / administration & dosage. Glucose Tolerance Test. Humans. Magnetic Resonance Imaging. Male. Periodicity. Prednisolone / administration & dosage. Risk Assessment. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Insulinoma.
  • MedlinePlus Health Information. consumer health - Hypoglycemia.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409607.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 9PHQ9Y1OLM / Prednisolone; IY9XDZ35W2 / Glucose
  •  go-up   go-down


68. Saif MW: Pancreatoblastoma. JOP; 2007;8(1):55-63
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pancreatoblastoma (PB), or infantile pancreatic carcinoma, is an extremely rare pancreatic tumor in childhood, comprising 0.5% of pancreatic non-endocrine tumors.
  • Mechanical obstruction of the upper duodenum and gastric outlet by tumor in the head of the pancreas may be associated with vomiting, jaundice and gastrointestinal bleeding.
  • The majority of these tumors arise in the head of the pancreas.
  • Ultrasound and CT scan may be useful but preoperative diagnosis is often quite difficult.
  • The treatment of choice is complete resection, that may often be curative.
  • The role of adjuvant chemotherapy or radiotherapy is still under discussion due to small number of patients treated as yet.
  • Chemotherapy regimens consisting of cyclophosphamide, etoposide, doxorubicin, and cisplatin have been used in neoadjuvant setting with anecdotal benefit.
  • Prognosis of this rare tumor is good, when resected completely.
  • On the whole, PB is regarded to be a curable tumor; hence the clinical diagnosis should be made early.
  • Awareness of this rare tumor of pancreas is essential for early detection and proper management.
  • The author review the clinical presentation, etiology, diagnosis, treatment and prognosis of PB in this presentation.
  • [MeSH-major] Carcinoma / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Infant. Male. Middle Aged. Pancreas / pathology

  • Genetic Alliance. consumer health - Pancreatoblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17228135.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


69. Matsuno S, Egawa S, Fukuyama S, Motoi F, Sunamura M, Isaji S, Imaizumi T, Okada S, Kato H, Suda K, Nakao A, Hiraoka T, Hosotani R, Takeda K: Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas; 2004 Apr;28(3):219-30
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Preoperative histologic diagnosis and diagnostic imaging are fundamentals in managing the disease, but it is not rare to find unexpected peritoneal dissemination or liver metastasis at the time of operation.
  • Resecting the portal vein and peripancreatic plexus were performed on 40% of the patients who underwent pancreatectomy for invasive cancer in the head of the pancreas.
  • Multidisciplinary treatments combined with surgery were performed, and various effects of postoperative chemotherapy after pancreatectomy, intraoperative- and postoperative-radiation therapy, or postoperative chemotherapy for unresectable tumor, were shown.
  • Development of unconventional therapies and refinement of the conventional therapy should be promoted on a randomized prospective trial basis.
  • To promote this effort, which requires the international comparisons and cooperation, JPS developed a computerized JPS registration system downloadable from the JPS website (http://www.kojin.or.jp/suizou/index.html).
  • [MeSH-major] Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy. Registries
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Combined Modality Therapy. Female. Humans. Japan. Lymph Node Excision. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Pancreatectomy. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15084961.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


70. Dolmans DE, Fukumura D, Jain RK: Photodynamic therapy for cancer. Nat Rev Cancer; 2003 May;3(5):380-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy for cancer.
  • The therapeutic properties of light have been known for thousands of years, but it was only in the last century that photodynamic therapy (PDT) was developed.
  • At present, PDT is being tested in the clinic for use in oncology--to treat cancers of the head and neck, brain, lung, pancreas, intraperitoneal cavity, breast, prostate and skin.
  • [MeSH-major] Neoplasms / drug therapy. Photochemotherapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12724736.001).
  • [ISSN] 1474-175X
  • [Journal-full-title] Nature reviews. Cancer
  • [ISO-abbreviation] Nat. Rev. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 128
  •  go-up   go-down


71. Nakamoto Y, Saga T, Ishimori T, Higashi T, Mamede M, Okazaki K, Imamura M, Sakahara H, Konishi J: FDG-PET of autoimmune-related pancreatitis: preliminary results. Eur J Nucl Med; 2000 Dec;27(12):1835-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this retrospective study was to elucidate the fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) findings in autoimmune-related pancreatitis (AIP), which is a reversible chronic pancreatitis with an autoimmune cause.
  • In four of the six patients, PET demonstrated intense uptake in the whole pancreas, which appeared swollen on computed tomography, and the accumulation increased with time in three patients.
  • In one patient, intense focal uptake in the pancreatic head was observed, and the accumulation decreased over time.
  • In the remaining patient, no abnormal accumulation in the pancreas was observed.
  • Follow-up PET scanning after steroid therapy was performed in three patients, and intense FDG uptake was no longer observed.
  • Our preliminary data show that AIP can cause intense FDG uptake in the pancreas.
  • This fact, and the benign status of the condition, should be kept in mind when making a diagnosis with FDG-PET in patients with pancreatic disorders.
  • [MeSH-minor] Cell Survival / drug effects. Chondrosarcoma / metabolism. Fibrosarcoma / metabolism. Humans. Liposarcoma / metabolism. Sarcoma, Synovial / metabolism. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11189947.001).
  • [ISSN] 0340-6997
  • [Journal-full-title] European journal of nuclear medicine
  • [ISO-abbreviation] Eur J Nucl Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Furans; 0 / Organophosphorus Compounds; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0 / technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane; 0 / technetium Tc 99m Q12; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


72. Takemura N, Kokudo N, Imamura H, Takazawa Y, Sano K, Sugawara Y, Nakagawa K, Ohtomo K, Makuuchi M: Eleven-year survivor of unresectable intrahepatic cholangiocarcinoma treated using long-term UFT therapy. Hepatogastroenterology; 2008 Nov-Dec;55(88):1997-9
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eleven-year survivor of unresectable intrahepatic cholangiocarcinoma treated using long-term UFT therapy.
  • We report a 49-year-old man with unresectable intrahepatic cholangiocarcinoma (ICC) who was treated with oral tegafur-uracil (UFT) chemotherapy and survived for over a decade.
  • In 1995, the patient was admitted to our institution after a large tumor in his left liver was detected using computed tomography (CT).
  • The tumor was diagnosed as ICC, and a laparotomy was performed; however, the tumor was too advanced to perform a curative resection.
  • The cancer had spread to the lymph nodes in the hepatoduodenal ligament and on the posterior surface of the pancreas head.
  • A curative resection was abandoned, and oral UFT chemotherapy was started immediately after the laparotomy.
  • The tumor remained almost unchanged until 2001 with only UFT administration; however, its size gradually increased to 7.8 cm in diameter.
  • External-beam radiotherapy (50.4 Gy) was performed, and the tumor's size decreased to 6.3 cm in diameter.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Bile Duct Neoplasms / drug therapy. Bile Duct Neoplasms / mortality. Bile Ducts, Intrahepatic. Cholangiocarcinoma / drug therapy. Cholangiocarcinoma / mortality. Tegafur / administration & dosage
  • [MeSH-minor] Adult. Combined Modality Therapy. Disease Progression. Humans. Male. Radiotherapy Dosage. Survivors

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19260466.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 1548R74NSZ / Tegafur
  •  go-up   go-down


73. Grenacher L, Klauss M: [Computed tomography of pancreatic tumors]. Radiologe; 2009 Feb;49(2):107-23
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Computed tomography of pancreatic tumors].
  • Computed tomography (CT) and in particular multi-detector row computed tomography (MDCT), also known as multislice CT (MSCT), is ideally suited for detecting pancreatic tumors because of the high spatial resolution.The method of choice is hydro-CT which involves distension of the stomach and duodenum by administration of 1-1.5 l water as a negative contrast medium under medically induced hypotension by administration of buscopan.
  • The patient is laid on the right side at an angle of 30-45 degrees in order to obtain an artefact-free image of the close anatomical relationship around the pancreas head.
  • In addition, curved MPRs or in rare cases 3D reconstructions could be very helpful in identifying the critical anatomic tumor site in the neighbourhood of the visceral vessel system.
  • After the correct diagnosis of an adenocarcinoma has been made only 20% of all patients are shown to have a surgically resectable disease, but the overall survival rate is significantly higher after resection in combination with a multimodal tumor therapy strategy.
  • The reason is that the correct diagnosis of the resectability of the tumor is one of the main criteria for overall survival of these patients.
  • Currently practically all pancreatic tumors can be detected using MDCT and the detection rate varies between 70% and 100% (most recent literature references give a sensitivity of 89% and specificity up to 99%).
  • MDCT is an ideal tool for the detection of neuroendocrine tumors, metastases and for the differentiation of cystic pancreatic lesions such as pseudocysts, microcystic adenomas or intraductal papillary mucinous neoplasms (IPMN).
  • Moreover MD-CT is an ideal procedure for the differentiation of local tumor stages in patients under neoadjuvant or adjuvant chemotherapy.
  • [MeSH-major] Image Processing, Computer-Assisted. Imaging, Three-Dimensional. Pancreatic Neoplasms / diagnostic imaging. Tomography, Spiral Computed
  • [MeSH-minor] Adenocarcinoma / diagnostic imaging. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenocarcinoma, Mucinous / diagnostic imaging. Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / diagnostic imaging. Carcinoma, Pancreatic Ductal / mortality. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / diagnostic imaging. Carcinoma, Papillary / mortality. Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Diagnosis, Differential. Disease-Free Survival. Humans. Neuroendocrine Tumors / diagnostic imaging. Neuroendocrine Tumors / mortality. Neuroendocrine Tumors / pathology. Neuroendocrine Tumors / surgery. Pancreas / diagnostic imaging. Pancreas / pathology. Pancreatectomy. Pancreatic Pseudocyst / diagnostic imaging. Prognosis. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Radiol. 2006 Nov;79(947):880-7 [16822803.001]
  • [Cites] AJR Am J Roentgenol. 2002 Sep;179(3):717-24 [12185052.001]
  • [Cites] Radiology. 2008 Sep;248(3):876-86 [18632526.001]
  • [Cites] Ann Surg. 2005 Sep;242(3):413-9; discussion 419-21 [16135927.001]
  • [Cites] Ann Surg. 1997 Oct;226(4):393-405; discussion 405-7 [9351708.001]
  • [Cites] J Gastrointest Surg. 2007 Mar;11(3):338-44 [17458608.001]
  • [Cites] Pancreatology. 2008;8(3):236-51 [18497542.001]
  • [Cites] Radiologe. 2003 Apr;43(4):293-300 [12721645.001]
  • [Cites] J Comput Assist Tomogr. 2005 Jul-Aug;29(4):438-45 [16012297.001]
  • [Cites] Pancreas. 2005 Apr;30(3):218-22 [15782097.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] N Engl J Med. 1992 Feb 13;326(7):455-65 [1732772.001]
  • [Cites] Am Surg. 2000 Apr;66(4):378-85; discussion 386 [10776876.001]
  • [Cites] Radiologe. 1998 Apr;38(4):279-86 [9622822.001]
  • [Cites] Radiographics. 2005 Nov-Dec;25(6):1471-84 [16284129.001]
  • [Cites] Eur Radiol. 2004 Jul;14 (7):1188-95 [15083335.001]
  • [Cites] Abdom Imaging. 2006 Sep-Oct;31(5):568-74 [16465578.001]
  • [Cites] J Clin Gastroenterol. 2008 Mar;42(3):284-94 [18223495.001]
  • [Cites] Eur Radiol. 2006 Aug;16(8):1709-18 [16550353.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Digestion. 2003;68(1):24-33 [12949436.001]
  • [Cites] J Comput Assist Tomogr. 2005 Mar-Apr;29(2):170-5 [15772532.001]
  • [Cites] Radiology. 2000 Jul;216(1):163-71 [10887243.001]
  • [Cites] Eur Radiol. 2003 Jan;13(1):149-56 [12541123.001]
  • [Cites] Radiologe. 2008 Aug;48(8):752-63 [18633589.001]
  • [Cites] Eur J Surg Oncol. 2007 Aug;33(6):678-84 [17207960.001]
  • [Cites] AJR Am J Roentgenol. 1997 Aug;169(2):459-64 [9242754.001]
  • [Cites] Eur J Radiol. 2007 Jun;62(3):371-7 [17433598.001]
  • [Cites] Chirurg. 2003 Mar;74(3):202-7 [12647076.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Cancer. 2006 Jun 25;108(3):163-73 [16550572.001]
  • [Cites] Histopathology. 2008 Apr;52(5):539-51 [17903202.001]
  • [Cites] N Engl J Med. 2004 Sep 16;351(12):1218-26 [15371579.001]
  • [Cites] Radiologe. 1996 May;36(5):397-405 [8778924.001]
  • [Cites] J Magn Reson Imaging. 2007 Jul;26(1):86-93 [17659551.001]
  • [Cites] Dtsch Med Wochenschr. 2007 Apr 13;132(15):813-7 [17427092.001]
  • [Cites] Arch Surg. 1998 Jan;133(1):61-5 [9438761.001]
  • [Cites] Ann Surg Oncol. 2006 Jan;13(1):75-85 [16372157.001]
  • [Cites] Pancreatology. 2008;8(2):199-203 [18434757.001]
  • [Cites] Radiology. 2006 Mar;238(3):912-9 [16439566.001]
  • [Cites] World J Surg. 2006 Aug;30(8):1553-9 [16773248.001]
  • [Cites] AJR Am J Roentgenol. 2003 Feb;180(2):475-80 [12540455.001]
  • [Cites] Pancreas. 2006 Aug;33(2):111-8 [16868475.001]
  • [Cites] JOP. 2007 Mar 10;8(2):214-22 [17356246.001]
  • [Cites] Pancreatology. 2008;8(2):135-41 [18382099.001]
  • [Cites] AJR Am J Roentgenol. 2003 May;180(5):1311-23 [12704043.001]
  • [Cites] Pancreatology. 2008;8(2):204-10 [18434758.001]
  • [Cites] Radiologe. 2006 May;46(5):421-37; quiz 438 [16715226.001]
  • [Cites] Rofo. 1998 Mar;168(3):211-6 [9551105.001]
  • [Cites] Ann Surg. 2004 May;239(5):678-85; discussion 685-7 [15082972.001]
  • [Cites] AJR Am J Roentgenol. 1990 Nov;155(5):995-6 [2120971.001]
  • [Cites] Surg Clin North Am. 1995 Oct;75(5):1001-16 [7660245.001]
  • [Cites] Ann Surg. 2004 Mar;239(3):400-8 [15075659.001]
  • [Cites] J Gastrointest Surg. 1999 May-Jun;3(3):233-43 [10481116.001]
  • [Cites] Eur Radiol. 2007 Mar;17(3):638-49 [17021700.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] AJR Am J Roentgenol. 2006 Dec;187(6):1513-20 [17114545.001]
  • [Cites] Pancreatology. 2009;9(5):621-30 [19657217.001]
  • [Cites] Ann Surg. 2007 Oct;246(4):644-51; discussion 651-4 [17893501.001]
  • [Cites] Radiology. 1993 Mar;186(3):799-802 [8381551.001]
  • [Cites] Pancreatology. 2001;1(6):648-55 [12120249.001]
  • [Cites] J Gastrointest Surg. 1998 Sep-Oct;2(5):472-82 [9843608.001]
  • [Cites] J Gastrointest Surg. 2008 Jan;12(1):101-9 [17917784.001]
  • (PMID = 19137277.001).
  • [ISSN] 1432-2102
  • [Journal-full-title] Der Radiologe
  • [ISO-abbreviation] Radiologe
  • [Language] ger
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 71
  •  go-up   go-down


74. Nakagawa Y, Todoroki T, Morishita Y, Mori K, Nakahaashi C, Ohkohchi N, Matsumoto H: A long-term survivor after pancreaticoduodenectomy for metastatic undifferentiated carcinoma of an unknown primary. Hepatogastroenterology; 2008 Sep-Oct;55(86-87):1557-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 53-year-old female had complaints of intermittent high fever and a large palpable epigastric tumor.
  • A CT scan revealed that a very large well-circumscribed solid mass occupied the posterior portion of the head of the pancreas and extended to the hepatic hilum.
  • Histologically, the tumor showed solid or diffuse proliferation of pleomorphic cells, and the immunohistochemistry suggested a metastatic tumor originating from the epithelium, the primary site was not determined despite of full review of all metastatic lesions to pancreas handled surgically and non-surgically.
  • Adjuvant oral chemotherapy of UFT and cimetidine continued for 3 years and the patient alive and healthy 6 years after surgery.
  • Even for dismal prognostic undifferentiated CUP, radical surgery would be an effective component of multidisciplinary treatment, provided that the tumor is respectable without elevation of serum tumor markers and adjuvant chemotherapy is able to appropriately supplement.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Middle Aged. Neoplasm Metastasis. Survivors. Tegafur / therapeutic use. Uracil / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19102342.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 1-UFT protocol
  •  go-up   go-down


75. Sheng L, Weixia Z, Longhai Y, Jinming Y: Clinical and biologic analysis of pancreatoblastoma. Pancreas; 2005 Jan;30(1):87-90
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since the first description of pancreatoblastoma as a malignant pancreatic tumor of childhood in 1957, approximately 200 cases have been reported.
  • During laparotomy, a 10 x 8 x 8-cm3 tumor was discovered in the pancreatic body and tail, and with 3 cystic masses, 15, 10, and 8 cm in diameter, respectively, involving the right lobe of the liver.
  • Pathologic examination of the resected tumor revealed findings characteristic of pancreatoblastoma.
  • The tumor formed acinar and glandular structures and solid areas and contained many "squamoid corpuscles," a defining feature of pancreatoblastoma.
  • In spite of adjuvant chemotherapy with Adriamycin and gemcitabine, the patient returned 11 months later with several large hepatic masses, invading the pancreatic head and enlarged tracheobronchial lymph nodes.
  • Radiotherapy, transcatheter arterial embolization therapy, and chemotherapy were performed.
  • Unfortunately, the patient died 26 months later from disseminated tumor progression.
  • Biologic study will investigate the molecular biology of this rare tumor.
  • The biology may help define prognosis and therapy for this kind of tumor.
  • [MeSH-major] Pancreas / pathology. Pancreas / radiography. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / radiography

  • Genetic Alliance. consumer health - Pancreatoblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15632705.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Miller CR, Williams CR, Buchsbaum DJ, Gillespie GY: Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. Cancer Res; 2002 Feb 1;62(3):773-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas.
  • 5-Fluorouracil (5-FU) is a potent antimetabolite used for chemotherapy of gastrointestinal (GI), breast, and head and neck malignancies.
  • Although clinical trials have been conducted, the poor therapeutic index of 5-FU has precluded its clinical use for a number of other tumor types.
  • It is unclear whether this lack of utility is due to problems with drug delivery or inherent insensitivity.
  • Adenovirus (Ad) vector-mediated cytosine deaminase (CD)/5-fluorocytosine (5-FC) gene therapy has the potential to overcome pharmacokinetic issues associated with systemic 5-FU and is particularly well suited to use with tumors in which local control is paramount, such as recurrent, localized prostate cancer and malignant gliomas.
  • In this study, the in vitro response by a panel of human tumor cell lines derived from both GI (colon, pancreas) and non-GI (prostate, glioma) tumors to 5-FU and to AdCMVCD (an Ad encoding Escherichia coli CD)/5-FC was examined.
  • Whereas the sensitivity (IC(50)) of individual cell lines to these agents varied, no significant difference in median IC(50) for either 5-FU or AdCMVCD/5-FC was evident for the four tumor types tested (P > 0.1).
  • Finally, the therapeutic efficacy of a single intratumoral injection of AdCMVCD followed by systemic 5-FC was assessed in three intracranial C.B17 severe combined immunodeficient mouse models of human glioma.
  • These results reveal that glioma cells are as sensitive as GI tumor cells to the antineoplastic effects of 5-FU, identify inherent 5-FU sensitivity as an important factor in determining CD/5-FC efficacy, and confirm previous findings in rat models that demonstrate the potential clinical utility of AdCMVCD/5-FC gene therapy for gliomas.
  • [MeSH-major] Antimetabolites, Antineoplastic / pharmacology. Brain Neoplasms / therapy. Flucytosine / pharmacokinetics. Fluorouracil / pharmacology. Genetic Therapy / methods. Glioblastoma / therapy. Nucleoside Deaminases / genetics. Prodrugs / pharmacokinetics
  • [MeSH-minor] Adenoviridae / genetics. Animals. Cytosine Deaminase. Genetic Vectors / administration & dosage. Genetic Vectors / genetics. Humans. Injections, Intralesional. Mice. Mice, SCID. Tumor Cells, Cultured. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUCYTOSINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11830532.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 71933; United States / NCI NIH HHS / CA / CA 73636
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Prodrugs; D83282DT06 / Flucytosine; EC 3.5.4.- / Nucleoside Deaminases; EC 3.5.4.1 / Cytosine Deaminase; U3P01618RT / Fluorouracil
  •  go-up   go-down


77. Demirkan B, Unek IT, Eriksson B, Akarsu M, Durak H, Sağol O, Obuz F, Binicier C, Füzün M, Alakavuklar M: A patient with nonfunctional pancreatic neuroendocrine tumor and incidental metachronous colon carcinoma detected by positron emission tomography: case report. Turk J Gastroenterol; 2009 Sep;20(3):214-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A patient with nonfunctional pancreatic neuroendocrine tumor and incidental metachronous colon carcinoma detected by positron emission tomography: case report.
  • Presence of a metachronous colon adenocarcinoma in a patient with nonfunctional pancreatic neuroendocrine tumor has not been reported before.
  • We present a patient who had an asymptomatic mass in the head of the pancreas, detected by ultrasonography in 1996.
  • In 2002, after the diagnosis of an unresectable, nonfunctional pancreatic neuroendocrine tumor, interferon alpha- 2b and octreotide were started.
  • A year after biological treatment, he refused further treatment.
  • In 2004, during the evaluation of dissemination of the asymptomatic disease, positron emission tomography revealed a high uptake by the descending colon despite the failure of other imaging methods.
  • After surgery for operable colon carcinoma, the patient received chemotherapy and biological therapy for both tumors.
  • Since 2005, he has been doing well without any further treatment thus far.
  • In conclusion, computerized tomography/magnetic resonance imaging and octreotide scintigraphy may be insufficient to show disseminated disease and asymptomatic second primary malignancies.
  • Therefore, positron emission tomography is a valuable promising option for the evaluation of gastroenteropancreatic neuroendocrine tumors and concomitant or metachronous malignancies.
  • Lifelong follow-up by a multidisciplinary oncology team is needed so that a long-term survival can be achieved with integrated multimodal systemic treatment approaches.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Colonic Neoplasms / radionuclide imaging. Neoplasms, Second Primary / radionuclide imaging. Neuroendocrine Tumors / radionuclide imaging. Pancreatic Neoplasms / radionuclide imaging. Positron-Emission Tomography

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19821205.001).
  • [ISSN] 2148-5607
  • [Journal-full-title] The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
  • [ISO-abbreviation] Turk J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


78. Piscitelli D, Sanguedolce F, Mattioli E, Parisi G, Fiore MG, Resta L: [Unusual presentation of metastatic osteosarcoma as a giant duodenal polyp. A case report]. Pathologica; 2005 Apr;97(2):88-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Osteosarcoma metastatico polipoide del duodeno. descrizione di un caso ad insolita presentazione.
  • INTRODUCTION: Osteosarcoma is a malignant bone neoplasm with an usually high metastatic potential.
  • Besides the common metastatic sites such as lungs, bone, and pleura, metastases to unusual sites such as liver, brain and regional lymph nodes have also been reported with increasing frequency; among them, gastrointestinal metastases represent an extraordinarily rare event in the natural history of this neoplasia.
  • MATERIALS AND METHODS: We describe a case of a 27 year old man, who was diagnosed with a grade IV osteoblastic osteosarcoma of the left tibia and submitted to 5 courses of pre-surgical chemotherapy; later he underwent tibial resection with implantation of a prosthesis, followed by 2 further courses of adjuvant chemotherapy.
  • Five years after the patient presented with melena and acute anemia; during endoscopic examination, a large bleeding duodenal polyp was found, so a surgical resection of the gastric antrum, duodenum, head of the pancreas, main bile ducts and gallbladder was performed.
  • RESULTS: Microscopically, the tumor mass showed a mostly fasciculated architecture, composed of spindle and epithelioid cells in a scarce fibromyxoid stroma, featuring large areas of coagulative necrosis and small foci of sclerohyalinosis.
  • Tumor cells featured large vesciculous nuclei, with a few prominent nucleoli; no foci of osteoid matrix were detectable.
  • Due to alteration of the natural history of the tumor induced by multiagent chemotherapy, the rate of metastases of osteosarcoma to unusual sites has been increasing.
  • Both the histological features and the immunohistochemical findings were not suggestive for osteosarcoma metastases because the tumor appeared dedifferentiated; in our case the combination of electron microscopy and clinical history played a pivotal role to establish the final diagnosis.

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16032954.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


79. Kalil AN, Reck dos Santos PA, Azambuja DB, Beck PE: A case of retroperitoneal lymphoma presenting as pancreatic tumor. Hepatogastroenterology; 2004 Jan-Feb;51(55):259-61
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of retroperitoneal lymphoma presenting as pancreatic tumor.
  • Abdominal ultrasonogram and computed tomography of the abdomen showed an mass in the head of pancreas with absence of extrapancreatic disease and no direct tumor extension to the portal vein or superior mesenteric artery.
  • He received chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone.
  • The patient is alive and in remission with a follow-up time of 24 months.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / diagnosis. Pancreatic Neoplasms / diagnosis. Retroperitoneal Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15011880.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


80. Vanwoerkom RC, Bentz J, Chen L, Adler DG: EUS diagnosis of a primary pancreatic metastasis of alveolar rhabdomyosarcoma. JOP; 2009;10(6):683-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EUS diagnosis of a primary pancreatic metastasis of alveolar rhabdomyosarcoma.
  • CASE REPORT: An 18-year-old man with a history of right orbital alveolar rhabdomyosarcoma, which had been treated with neoadjuvant therapy, surgery and adjuvant chemotherapy developed an episode of pancreatitis.
  • CT at that time demonstrated acute pancreatitis with no mass lesions.
  • Two months later, the patient developed abdominal pain and an MRI documented a 6.4 cm mass in the pancreatic body and tail.
  • EUS guided FNA confirmed the diagnosis of alveolar rhabdomyosarcoma metastatic to the pancreas.
  • CONCLUSION: To our knowledge this is the first reported case of EUS guided FNA diagnosis of alveolar rhabdomyosarcoma metastatic to the pancreas.
  • This is also the only case report of a primary pancreatic metastasis of this type of tumor in a male patient (which occurs less commonly than in females).
  • [MeSH-major] Head and Neck Neoplasms / secondary. Head and Neck Neoplasms / ultrasonography. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / ultrasonography. Rhabdomyosarcoma, Alveolar / ultrasonography

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19890194.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


81. Bauditz J, Rudolph B, Wermke W: Osteoclast-like giant cell tumors of the pancreas and liver. World J Gastroenterol; 2006 Dec 28;12(48):7878-83
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteoclast-like giant cell tumors of the pancreas and liver.
  • Osteoclast-like giant cell tumors (OGCT) are rare abdominal tumors, which mainly occur in the pancreas.
  • Here we report on two cases of osteoclast-like giant cell tumors, one located within the pancreas, the other within the liver, in which OGCTs are extremely rare.
  • Both patients were investigated by contrast sonography, which demonstrated a complex, partly cystic and strongly vascularized tumor within the head of the pancreas in the first patient and a large, hypervascularized neoplasm with calcifications within the liver in the second patient.
  • With a combination of surgical resection, radiofrequency ablation and chemotherapy, the patient's survival is currently more than 15 mo, making him the longest survivor with an OGCT of the liver to date.
  • [MeSH-minor] Combined Modality Therapy. Diagnosis, Differential. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2000 Oct;31(10):1223-9 [11070115.001]
  • [Cites] J Korean Med Sci. 2005 Jun;20(3):516-20 [15953882.001]
  • [Cites] Int J Clin Oncol. 2002 Dec;7(6):376-80 [12494256.001]
  • [Cites] Pathol Int. 2003 Jul;53(7):450-6 [12828610.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Jul;19(7):761-6 [15209622.001]
  • [Cites] Cancer. 1968 Aug;22(2):333-44 [5660199.001]
  • [Cites] Cancer. 1977 Mar;39(3):1181-9 [912652.001]
  • [Cites] Cancer. 1980 Aug 15;46(4):771-9 [6994872.001]
  • [Cites] Cancer. 1984 Sep 1;54(5):837-42 [6331629.001]
  • [Cites] Tumori. 1985 Dec 31;71(6):615-20 [3001983.001]
  • [Cites] Acta Pathol Jpn. 1987 Aug;37(8):1327-35 [3673575.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1988;412(3):247-53 [3124345.001]
  • [Cites] Am J Clin Pathol. 1990 Jan;93(1):111-6 [2153001.001]
  • [Cites] Cancer. 1992 May 15;69(10):2444-8 [1314689.001]
  • [Cites] Pancreas. 1992;7(5):611-5 [1513808.001]
  • [Cites] Pathol Res Pract. 1993 Mar;189(2):228-31; discussion 232-4 [8321752.001]
  • [Cites] Histopathology. 1993 Aug;23(2):187-9 [8406392.001]
  • [Cites] Br J Radiol. 1993 Nov;66(791):1055-7 [8281385.001]
  • [Cites] Aust N Z J Surg. 1996 May;66(5):334-5 [8634058.001]
  • [Cites] Pathol Int. 1997 May;47(5):318-24 [9143028.001]
  • [Cites] Virchows Arch. 1997 Sep;431(3):215-8 [9334844.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1279-87 [9529019.001]
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1247-54 [9777987.001]
  • [Cites] Pancreas. 1999 Apr;18(3):308-15 [10206490.001]
  • [Cites] J Gastrointest Surg. 2005 Feb;9(2):207-14 [15694816.001]
  • [Cites] Histopathology. 2005 May;46(5):590-2 [15842645.001]
  • [Cites] Pancreatology. 2005;5(2-3):279-84 [15849490.001]
  • [Cites] Am J Clin Oncol. 2001 Feb;24(1):77-80 [11232955.001]
  • (PMID = 17203538.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4087560
  •  go-up   go-down


82. Ueda K, Nagayama Y, Narita K, Kusano M, Mernyei M, Kamiya M: Pancreatic involvement by non-Hodgkin's lymphoma. J Hepatobiliary Pancreat Surg; 2000;7(6):610-3
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient, a 63-year-old man had a large tumor in the head of the pancreas, without obstructive jaundice.
  • Invasion of the tumor into the duodenum and transverse colon induced progressive anemia and ileus.
  • Therefore, pancreatoduodenectomy and right hemicolectomy were performed, although a definitive preoperative diagnosis was not obtained.
  • This tumor was identified, by histopathology and immunohistochemistry, as diffuse mixed type lymphoma with a B-cell phenotype.
  • Postoperatively, the patient had severe congestive heart failure, and he died without receiving chemotherapy.
  • It is important to establish a definitive diagnosis for this disease, to remove the tumor, and to treat the patient with appropriate chemotherapy.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Fatal Outcome. Heart Neoplasms / radiography. Heart Neoplasms / secondary. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11180896.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


83. Koizumi M, Sata N, Kasahara N, Morishima K, Sasanuma H, Sakuma Y, Shimizu A, Hyodo M, Yasuda Y: Remnant pancreatectomy for recurrent or metachronous pancreatic carcinoma detected by FDG-PET: two case reports. JOP; 2010;11(1):36-40
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Although surgical resection is the only curative therapeutic option for recurrent or metachronous pancreatic carcinomas, most such cancers are beyond surgical curability.
  • CASE REPORTS: CASE#1 A 65-year-old male developed weight loss and diabetes mellitus 83 months after a pylorus-preserving pancreaticoduodenectomy followed by two years of adjuvant chemotherapy (5-fluorouracil plus leucovorin plus mitomycin C) for a pancreatic carcinoma in the head of the pancreas (stage IA).
  • An abdominal CT scan revealed a 3 cm tumor in the remnant pancreas which appeared as a 'hot' nodule on FDG-PET.
  • A remnant distal pancreatectomy was performed and a pancreatic carcinoma similar in profile to the primary lesion (stage IIB) was confirmed pathologically.
  • CASE#2 A 67-year-old male showed increased CA 19-9 levels 25 months after a distal pancreatectomy for a pancreatic carcinoma in the body of the pancreas (stage IA).
  • An abdominal CT scan revealed a cystic lesion in the cut end of the pancreas which appeared as a 'hot' nodule on FDG-PET.
  • CONCLUSION: Remnant pancreatectomy can be considered a treatment option for recurrent or metachronous pancreatic carcinomas.
  • [MeSH-major] Carcinoma / surgery. Neoplasm Recurrence, Local / surgery. Neoplasms, Second Primary / surgery. Pancreatectomy. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Aged. Fluorodeoxyglucose F18. Humans. Male. Neoplasm, Residual

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20065550.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


84. Hackert T, Büchler MW, Werner J: Surgical options in the management of pancreatic cancer. Minerva Chir; 2009 Oct;64(5):465-76
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Management of pancreatic cancer is an interdisciplinary challenge as this tumor entity is still characterized by a poor prognosis and an overall long-term survival of only 1-5%.
  • A major problem is the early detection since 80-90% of pancreatic cancers are locally or systemically advanced at the time of diagnosis.
  • Yet, surgical therapy has to be embedded in an oncological concept of adjuvant treatment as postoperative chemotherapy is a key factor to further improve patient survival.
  • Numerous ongoing studies on new therapeutic agents like antibodies, antimetabolites and supportive agents reflect the current scientific and clinical struggle to achieve better outcome of pancreatic cancer patients in the future on the basis of initial tumor resection or if this is not possible as a palliative treatment.
  • Standard resections include partial pancreatico-duodenectomy with distal gastric resection or recently accepted as the preferable procedure preservation of the pylorus for tumors in the head of the pancreas, distal pancreatectomy for tumors of the corpus and tail as well as total pancreatectomy for more extended tumors or intraductal papillary mucinous neoplasias if necessary.
  • [MeSH-minor] Humans. Pancreaticoduodenectomy. Postoperative Complications / etiology. Postoperative Complications / therapy

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19859037.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


85. Hopt UT: [Treatment of carcinoma of the pancreatic head]. Zentralbl Chir; 2006 Apr;131(2):115-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of carcinoma of the pancreatic head].
  • [Transliterated title] Therapie des Pankreaskopfkarzinoms.
  • For patients with carcinoma in the head of the pancreas surgical resection remains the only chance of cure.
  • Only a small percentage of all patients suffering from pancreas carcinoma are good candidates for an operative therapy.
  • The most frequent contraindications are metastases in the liver or the peritoneum or a locally too advanced tumor.
  • The extent of surgical resection necessary in patients with pancreas carcinoma is still in discussion.
  • A substantial improvement of long term- survival can only be expected from new multimodal therapeutic strategies.
  • Adjuvant chemotherapy should strongly be recommended after resection of a pancreas carcinoma.
  • Neoadjuvant therapy on the other hand is still an experimental procedure and under evaluation in ongoing prospective randomized studies.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoadjuvant Therapy. Pancreatectomy / methods. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Disease Progression. Humans. Lymph Node Excision / methods. Neoplasm Staging. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic. Survival Rate

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16612777.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


86. Kianmanesh R, O'toole D, Sauvanet A, Ruszniewski P, Belghiti J: [Surgical treatment of gastric, enteric, and pancreatic endocrine tumors Part 1. Treatment of primary endocrine tumors]. J Chir (Paris); 2005 May-Jun;142(3):132-49
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of gastric, enteric, and pancreatic endocrine tumors Part 1. Treatment of primary endocrine tumors].
  • [Transliterated title] Traitement chirurgical des tumeurs endocrines gastro-entéro-pancréatiques.
  • They are classified into two principal types: gastrointestinal ET's (formerly called carcinoid tumors) which are the most common, and pancreaticoduodenal ET's.
  • Poorly-differentiated ET's have a poor prognosis and are treated by chemotherapy.
  • Surgical excision is the only curative treatment of well-differentiated ET's.
  • The surgical goals are to: 1. prolong survival by resecting the primary tumor and any nodal or hepatic metastases, 2. control the symptoms related to hormonal secretion, 3. prevent or treat local complications.
  • The most common sites of gastrointestinal ET's ( carcinoids) are the appendix and the rectum; these are often small (<1 cm), benign, and discovered fortuitously at the time of appendectomy or colonoscopic removal.
  • They are usually malignant and of advanced stage at diagnosis presenting as a palpable or obstructing mass or as liver metastases.
  • Insulinoma and gastrinoma (cause of the Zollinger-Ellison syndrome) are the most common functional ET's. 80% are sporadic; in these cases, tumor size, location, and malignant potential determine the type of resection which may vary from a simple enucleation to a formal pancreatectomy.
  • In 10-20% of cases, pancreaticoduodenal ET presents in the setting of multiple endocrine neoplasia (NEM type I), an autosomal-dominant genetic disease with multifocal endocrine involvement of the pituitary, parathyroid, pancreas, and adrenal glands.
  • For insulinoma with NEM-I, enucleation of lesions in the pancreatic head plus a caudal pancreatectomy is the most appropriate procedure.
  • [MeSH-major] Carcinoid Tumor / surgery. Carcinoma, Islet Cell / surgery. Carcinoma, Neuroendocrine / surgery. Insulinoma / surgery. Intestinal Neoplasms / surgery. Multiple Endocrine Neoplasia Type 1 / surgery. Pancreatic Neoplasms / surgery. Stomach Neoplasms / surgery. Zollinger-Ellison Syndrome / surgery
  • [MeSH-minor] Adult. Gastrinoma / diagnosis. Gastrinoma / surgery. Glucagonoma / diagnosis. Glucagonoma / surgery. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Malignant Carcinoid Syndrome / diagnosis. Malignant Carcinoid Syndrome / surgery. Multicenter Studies as Topic. Pancreatectomy. Postoperative Care. Postoperative Complications. Prognosis. Somatostatinoma / diagnosis. Somatostatinoma / surgery. Vipoma / diagnosis. Vipoma / surgery

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142076.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 236
  •  go-up   go-down


87. Doi T, Homma H, Mezawa S, Akiyama T, Machida T, Murakami K, Hirata K, Takanashi N, Iyama S, Niitsu Y: [Usefulness of CT arteriography for transcatheter peripancreatic arterial embolization to patients with advanced pancreatic cancer]. Gan To Kagaku Ryoho; 2002 Nov;29(12):2298-301
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We reported previously the clinical benefit of hepatic and splenic arterial infusion chemotherapy (HSAIC) for patients with advanced pancreatic cancer alter transcatheter peripancreatic arterial embolization (TPPAE).
  • TPPAE has two therapeutic purposes:.
  • (1) preparation for effective arterial infusion chemotherapy, and (2) transcatheter arterial embolization (TAE) against pancreas head cancer.
  • Since the anti-tumor effect of TPPAE against pancreas head cancer is dependent mainly on whether the blood supply from SMA could be shut off, it is suggested that CTA is useful to evaluate the embolization effect of TPPAE.
  • [MeSH-major] Angiography. Embolization, Therapeutic / methods. Pancreatic Neoplasms / therapy. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12484059.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


88. Wehrschütz M, Stöger H, Ploner F, Hofmann G, Wolf G, Höfler G, Krippl P, Samonigg H: Seminoma metastases mimicking primary pancreatic cancer. Onkologie; 2002 Aug;25(4):371-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Abdominal CT scan showed a tumor in the head of the pancreas and multiple pathologically enlarged peripancreatic lymph nodes.
  • A laparoscopic biopsy out of a suspicious lesion of the head of the pancreas and a surrounding lymph node was done.
  • 4 cycles of chemotherapy including cisplatinum, etoposide and bleomycin led into complete response that is still ongoing.
  • CONCLUSION: This case shows a seminoma with metastases at retroperitoneal site, mimicking a primary pancreatic neoplasm.
  • It provides an example of the possibility of an uncommon clinical appearance of seminoma metastases and again underlines the importance of exact radiological and histopathological examination to distinguish between curable and incurable tumor.
  • [MeSH-major] Pancreatic Neoplasms / secondary. Seminoma / secondary. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Biopsy. Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnosis, Differential. Follow-Up Studies. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Pancreas / pathology. Tomography, X-Ray Computed


89. Radford IR: Gd-Tex Pharmacyclics Inc. Curr Opin Investig Drugs; 2000 Dec;1(4):524-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pharmacyclics is developing Gd-Tex (gadolinium texaphyrin) as a radiosensitizer for the potential treatment of various cancers including brain metastases and primary brain tumors, pancreatic tumors, lung tumors and pediatric cancers [196711], [348919].
  • Phase I clinical trials for the treatment of primary brain tumors and pancreatic cancer have been initiated while several trials in other cancer types are in the planning stages [367716].
  • In September 1998, Pharmacyclics announced the initiation of a pivotal phase III trial for the treatment of patients with brain metastases.
  • The first was to determine the safety of two different dosing regimens of the drug during preoperative radiotherapy after induction chemotherapy in patients with stage IIA non-small cell lung cancer (NSCLC).
  • At the ASCO 1998 meeting, interim tumor response data were presented for 37 patients.
  • The overall tumor response rate (complete plus partial response rate) was 73%.
  • Full results were announced in October 1998 at the American Society of Therapeutic Radiology and Oncology.
  • Following ten daily injections followed by whole brain radiation, 77.7% of patients demonstrated a tumor response defined as greater than 50% reduction in tumor volume.
  • Death due to tumor progression was seen in 15% of the Gd-Tex group as opposed to 35% in the control group [302872].
  • In March 1997 the Decision Network of the NCI voted to sponsor additional clinical indications including adult and pediatric brain tumors, as well as cancers involving the lung, head & neck, pancreas and prostrate.
  • Two phase I trials of Gd-Tex for the treatment of primary brain tumors commenced in August 1998 under a CRADA with the NCI [237538], [295592], [348919].
  • [MeSH-major] Drugs, Investigational / therapeutic use. Neoplasms / therapy. Organometallic Compounds / therapeutic use. Radiation-Sensitizing Agents / therapeutic use

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11249709.001).
  • [ISSN] 1472-4472
  • [Journal-full-title] Current opinion in investigational drugs (London, England : 2000)
  • [ISO-abbreviation] Curr Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drugs, Investigational; 0 / Gd-Tex complex; 0 / Organometallic Compounds; 0 / Radiation-Sensitizing Agents
  • [Number-of-references] 33
  •  go-up   go-down


90. Egorov AV, Kuzin NM, Kondrashin SA, Lotov AN, Kazantseva IA, Kuznetsov NS, Gurevich LE, Lakreeva MG: [Treatment of malignant pancreatic islet cell tumors]. Khirurgiia (Mosk); 2000;(5):13-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of malignant pancreatic islet cell tumors].
  • Among 142 patients with islet cell tumor who were admitted to hospital between 1982 and 1999, 15 patients (10.6%) had malignant tumours.
  • Islet cell tumors were located in the head and corpus of the pancreas in 26.6% and 26.6% of the patients, respectively, in the tail of the pancreas in 46.8% of the patients.
  • The mean size of the tumor was 2.9 +/- 0.7 cm, in 6 patients (40%) liver metastases were found.
  • US, CT and angiography which sensitivity were 72.7, 100 and 85.7%, respectively, were used for topical diagnosis of the islet cell tumors.
  • Surgical procedures included distal pancreatic resection (n = 11), enucleation of the tumor (n = 2), hepatic resection (n = 1), abdominal exploration (n = 1).
  • In 2 patients palliative pancreatic resections were combined with transarterial embolization and devascularisation of the liver metastases and 2 patients were treated by systemic chemotherapy.
  • In other cases to determine the diagnosis was possible only after planned histological identification of the resected specimens.
  • 5-year survival rates after conservative and surgical treatment were 33% and 62.5%, respectively.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Islet Cell / therapy. Chemoembolization, Therapeutic. Pancreatectomy. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Adult. Female. Humans. Liver Neoplasms / mortality. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Male. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10842959.001).
  • [ISSN] 0023-1207
  • [Journal-full-title] Khirurgiia
  • [ISO-abbreviation] Khirurgiia (Mosk)
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] RUSSIA
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


91. Kim ES: Epidermal growth factor receptor as a target in cancer therapy. J Natl Compr Canc Netw; 2003 Jan;1 Suppl 1:S87-95
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor as a target in cancer therapy.
  • These include head and neck, breast, colon, lung, prostate, kidney, ovary, brain, pancreas, and bladder.
  • A number of strategies to block EGFR have been developed to inhibit tumor proliferation and to improve overall clinical outcome because overexpression of the receptor has been associated with a poorer prognosis in cancer patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Receptor, Epidermal Growth Factor / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19795581.001).
  • [ISSN] 1540-1405
  • [Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN
  • [ISO-abbreviation] J Natl Compr Canc Netw
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Number-of-references] 86
  •  go-up   go-down


92. Ali S, Varghese L, Pereira L, Tulunay-Ugur OE, Kucuk O, Carey TE, Wolf GT, Sarkar FH: Sensitization of squamous cell carcinoma to cisplatin induced killing by natural agents. Cancer Lett; 2009 Jun 18;278(2):201-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cisplatin resistance is a major problem in the successful treatment of squamous cell carcinoma (SCC).
  • In the present study we showed, for the first time, that the constitutive activation of NF-kappaB partly contributes to cisplatin resistance and that the inactivation of NF-kappaB by natural agents [G2535 (isoflavone mixture containing genistein and diadzein), 3,3'-diindolylmethane (Bioresponse BR-DIM referred to as B-DIM)] could overcome this resistance, resulting in the inhibition of cell growth and induction of apoptosis, which might be an useful strategy for achieving better treatment outcome in patients diagnosed with cisplatin-resistant tumors of SCC.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma, Squamous Cell / drug therapy. Cisplatin / pharmacology. Genistein / pharmacology. Indoles / pharmacology. Isoflavones / pharmacology
  • [MeSH-minor] Apoptosis / drug effects. Cell Line, Tumor. Cell Survival / drug effects. DNA / metabolism. Humans. Inhibitor of Apoptosis Proteins. Microtubule-Associated Proteins / genetics. NF-kappa B / antagonists & inhibitors. NF-kappa B / metabolism. Proto-Oncogene Proteins c-bcl-2 / genetics. bcl-X Protein / genetics

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. GENISTEIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Otolaryngol Head Neck Surg. 2008 Apr;134(4):363-9 [18427001.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):187-91 [17996392.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 Jul;8(7):1023-32 [18588449.001]
  • [Cites] Gynecol Oncol. 2008 Sep;110(3 Suppl 2):S4-7 [18760711.001]
  • [Cites] Mol Cancer Res. 2008 Sep;6(9):1499-506 [18723829.001]
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] Int J Epidemiol. 2000 Apr;29(2):197-207 [10817114.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4 Suppl 8):34-8 [10952436.001]
  • [Cites] Oncogene. 2000 Nov 23;19(50):5764-71 [11126363.001]
  • [Cites] Mutat Res. 2001 Jul 1;478(1-2):23-43 [11406167.001]
  • [Cites] Curr Opin Oncol. 2002 May;14(3):334-42 [11981281.001]
  • [Cites] Annu Rev Nutr. 2002;22:19-34 [12055336.001]
  • [Cites] Carcinogenesis. 2002 Aug;23(8):1297-305 [12151347.001]
  • [Cites] FASEB J. 2002 Oct;16(12):1550-7 [12374777.001]
  • [Cites] Cancer Metastasis Rev. 2002;21(3-4):265-80 [12549765.001]
  • [Cites] Nutr Cancer. 2003;45(1):101-12 [12791510.001]
  • [Cites] Br J Cancer. 2003 Jul 21;89(2):391-7 [12865934.001]
  • [Cites] Pancreas. 2004 May;28(4):e90-5 [15097869.001]
  • [Cites] Cell Stress Chaperones. 2004 Mar;9(1):76-87 [15270080.001]
  • [Cites] Am J Otolaryngol. 1980 Aug;1(4):306-23 [6160777.001]
  • [Cites] J Otolaryngol. 1984 Apr;13(2):99-104 [6202878.001]
  • [Cites] Crit Rev Oncol Hematol. 1984;1(4):323-55 [6085038.001]
  • [Cites] J Clin Microbiol. 1996 Mar;34(3):738-44 [8904450.001]
  • [Cites] Chem Biol Interact. 1997 Feb 28;103(2):79-129 [9055870.001]
  • [Cites] Mol Cancer Ther. 2004 Nov;3(11):1421-6 [15542781.001]
  • [Cites] Front Biosci. 2005 Jan 1;10:236-43 [15574364.001]
  • [Cites] Cancer Radiother. 2005 Feb;9(1):31-6 [15804617.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Jul;56(1):46-54 [15791457.001]
  • [Cites] Mol Carcinog. 2005 Sep;44(1):51-9 [16044419.001]
  • [Cites] Cancer Res. 2005 Aug 1;65(15):6934-42 [16061678.001]
  • [Cites] Mol Cancer Ther. 2006 Mar;5(3):556-63 [16546969.001]
  • [Cites] Carcinogenesis. 2006 Apr;27(4):717-28 [16332727.001]
  • [Cites] Nature. 2006 May 25;441(7092):431-6 [16724054.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10553-9 [17079479.001]
  • [Cites] J Bioinform Comput Biol. 2007 Apr;5(2a):383-405 [17589967.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007;69(2 Suppl):S106-8 [17848273.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8800-9 [17875721.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Gan To Kagaku Ryoho. 2008 May;35(5):745-52 [18487911.001]
  • (PMID = 19231069.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA097248; United States / NCI NIH HHS / CA / P50 CA097248-07
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BCL2L1 protein, human; 0 / BIRC5 protein, human; 0 / Indoles; 0 / Inhibitor of Apoptosis Proteins; 0 / Isoflavones; 0 / Microtubule-Associated Proteins; 0 / NF-kappa B; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-X Protein; 6287WC5J2L / daidzein; 9007-49-2 / DNA; DH2M523P0H / Genistein; Q20Q21Q62J / Cisplatin; SSZ9HQT61Z / 3,3'-diindolylmethane
  • [Other-IDs] NLM/ NIHMS371211; NLM/ PMC3350786
  •  go-up   go-down


93. Chang DT, Schellenberg D, Shen J, Kim J, Goodman KA, Fisher GA, Ford JM, Desser T, Quon A, Koong AC: Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer; 2009 Feb 1;115(3):665-72
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas.
  • METHODS: Seventy-seven patients with unresectable adenocarcinoma of the pancreas received 25 gray (Gy) in 1 fraction.
  • Sixteen patients (21%) received between 45 to 54 Gy of fractionated radiotherapy and SBRT.
  • Various gemcitabine-based chemotherapy regimens were received by 74 patients (96%), but 3 patients (4%) did not receive chemotherapy until they had distant failure.
  • There was no difference in the 12-month FFLP rate based on tumor location (head/uncinate, 91% vs body/tail, 86%; P = .52).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Recurrence. Retrospective Studies. Survival Analysis. Time Factors

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • [CommentIn] Cancer. 2009 Feb 1;115(3):468-72 [19117338.001]
  • (PMID = 19117351.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


94. Faraj W, Jamali F, Khalifeh M, Hashash J, Akel S: Solid pseudopapillary neoplasm of the pancreas in a 12-year-old female: case report and review of the literature. Eur J Pediatr Surg; 2006 Oct;16(5):358-61
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid pseudopapillary neoplasm of the pancreas in a 12-year-old female: case report and review of the literature.
  • Solid pseudopapillary neoplasms of the pancreas (SPNP) are rare pancreatic tumors that occur predominantly in young women, with very few cases reported in men.
  • While the origin of the tumor may be unclear, it is characterized by a distinct histological appearance and a clinical course highlighting its low malignant potential.
  • The role of chemotherapy and radiation therapy in the management of SPNP is still controversial.
  • We report here on an unusual occurrence of SPNP in the area of the head of the pancreas in a 12-year-old female treated by pancreatico-duodenectomy, together with a review of the literature.
  • [MeSH-minor] Child. Female. Humans. Pancreaticoduodenectomy. Prognosis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17160784.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 13
  •  go-up   go-down


95. Patel VG, Eltayeb OM, Henderson VJ, Lyons R, Martin D, Hamami A, Fortson JK, Weaver WL: Primary duodenal low-grade mucosa-associated lymphoid tissue lymphoma presenting with outlet obstruction. Am Surg; 2004 Jul;70(7):613-6
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary duodenal low-grade mucosa-associated lymphoid tissue lymphoma presenting with outlet obstruction.
  • Low-grade lymphoma arising in mucosa-associated lymphoid tissue (MALT) of the duodenum represents a very rare neoplasm.
  • Abdominal CT scan revealed a mass in either the duodenum or head of the pancreas.
  • The patient developed severe nausea, vomiting, and fullness after meals.
  • Pathological examination of the resected specimen revealed a low-grade B-cell lymphoma (MALToma) arising in the duodenum and invading the pancreas.
  • Celiac, peripancreatic, pelvic, and cervical nodes were also involved with tumor.
  • The patient was postoperatively treated with chemotherapy for stage IV disease.
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15279185.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Rich T, Harris J, Abrams R, Erickson B, Doherty M, Paradelo J, Small W Jr, Safran H, Wanebo HJ: Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-98-12. Am J Clin Oncol; 2004 Feb;27(1):51-6
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Unresectable cancer of the pancreas was treated with the combination of weekly paclitaxel and external beam irradiation in an effort to improve palliation and extend life expectancy.
  • Unresectable cancer was based on imaging studies (computed tomography or magnetic resonance imaging), all had histologic proof of adenocarcinoma, and none had evidence of metastatic disease or peritoneal seeding.
  • Image-guided radiotherapy treatment consisted of 50.4 Gy in 28 fractions over 5.5 weeks with coplanar anterior/posterior and lateral ports.
  • An initial dose of 45 Gy was given to fields covering the primary tumor plus the regional peripancreatic, celiac, and porta hepatis lymph nodes.
  • A cone down field was used for the last three fractions to encompass the gross tumor volume with a 1- to 1.5-cm margin.
  • The primary tumor was located in the pancreatic head in 65%.
  • Field placement, total dose, fractionation, and overall treatment time were given per protocol in greater than or equal to 90%.
  • Acute toxicity (worst per patient) occurred in 39% with grade III (35% of these were asymptomatic neutropenia), 5% with grade IV, and one patient died of infection during the fourth cycle of chemotherapy (grade V).
  • The median follow-up time for alive patients is 20.6 months (range 5-30).
  • These data provide the basis for a new Radiation Therapy Oncology Group trial using paclitaxel and irradiation combined with a second radiation sensitizer, gemcitabine, now under way.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Paclitaxel / therapeutic use. Palliative Care. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Dose Fractionation. Female. Humans. Male. Middle Aged. Survival Analysis


97. Pingpank JF, Hoffman JP, Ross EA, Cooper HS, Meropol NJ, Freedman G, Pinover WH, LeVoyer TE, Sasson AR, Eisenberg BL: Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg; 2001 Mar-Apr;5(2):121-30
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas.
  • We examined the effect of preoperative chemoradiotherapy on the ability to obtain pathologically negative resection margins in patients undergoing pancreaticoduodenectomy for adenocarcinoma of the head of the pancreas.
  • Between 1987 and 2000, 100 patients underwent Whipple resection with curative intent for primary adenocarcinoma of the head of the pancreas.
  • Pathologic assessment of six margins (proximal and distal superior mesenteric artery, proximal and distal superior mesenteric vein, pancreas, retroperitoneum, common bile duct, and hepatic artery) was undertaken by either frozen section (pancreas and common duct) or permanent section.
  • A margin was considered positive if tumor was present less than 1 mm from the inked specimen.
  • Of the 100 patients treated, 47 (47%) underwent postoperative radiation and chemotherapy (group I) and 53 (53%) received preoperative chemoradiotherapy (group II) with either 5-fluorouracil (32 patients) or gemcitabine (21 patients).
  • Patient demographics and operative parameters were similar in the two groups, with the exception of preoperative tumor size (CT scan), which was greater in group II (P < 0.001), and number of previous operations, which was greater in group II (P < 0.0001).
  • Statistical analysis of the number of negative surgical margins clear of tumor was performed using Fisher's exact test.
  • All patients (100%) had six margins assessed for microscopic involvement with tumor.
  • In the preoperative therapy group, 5 (7.5%) of 53 patients had more than one positive margin, whereas 21 (44.7%) of 47 patients without preoperative therapy had more than one margin with disease extension (P < 0.001).
  • Additionally, only 11 (25.6%) of the 47 patients without preoperative therapy had six negative margins vs. 27 (50.9%) of 53 in the group receiving preoperative therapy (P = 0.013).
  • However, this has not yet resulted in a significant increase in disease-free or overall survival for patients receiving preoperative therapy (P = 0.07).
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Female. Fluorouracil / therapeutic use. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Pancreaticoduodenectomy. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1987 Sep;206(3):366-73 [2820322.001]
  • [Cites] Am Surg. 2000 Apr;66(4):378-85; discussion 386 [10776876.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3 [7794076.001]
  • [Cites] Ann Surg. 1993 Feb;217(2):144-8 [8094952.001]
  • [Cites] Ann Surg. 1979 Feb;189(2):205-8 [426553.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1137-43 [1938511.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):928-37 [9060530.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] J Surg Oncol. 2000 Apr;73(4):212-8 [10797334.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Jan;14(1):79-84 [3121546.001]
  • [Cites] Cancer. 1987 Jun 15;59(12):2006-10 [3567862.001]
  • [Cites] Ann Surg. 1986 Jul;204(1):65-71 [3015059.001]
  • [Cites] Ann Surg. 1996 Mar;223(3):273-9 [8604907.001]
  • [Cites] Cancer. 1980 Nov 1;46(9):1945-9 [7427900.001]
  • [Cites] Cancer. 1976 Mar;37(3):1519-24 [1260670.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):227-32 [7799024.001]
  • [Cites] Semin Oncol. 1992 Aug;19(4 Suppl 11):96-101 [1509287.001]
  • [Cites] Ann Surg Oncol. 1999 Jan-Feb;6(1):117-22 [10030424.001]
  • [Cites] Arch Surg. 1985 Aug;120(8):899-903 [4015380.001]
  • [Cites] World J Surg. 1997 Feb;21(2):195-200 [8995078.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):161-7 [8083109.001]
  • (PMID = 11331473.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


98. Ochi N, Takigawa N, Yasugi M, Ishida E, Kawamoto H, Taniguchi A, Harada D, Hayashi E, Toda H, Yanai H, Tanimoto M, Kiura K: Obstructive jaundice at the initial presentation in small-cell lung cancer. Int Med Case Rep J; 2010;3:9-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This report presents the cases of two SCLC patients with obstructive jaundice at the initial diagnosis.
  • A 64-year-old male presented with obstructive jaundice due to a tumor at the head of the pancreas.
  • He was diagnosed with SCLC by transbronchial biopsy from a lung tumor in the left upper lobe.
  • Another 74-year-old male was admitted with jaundice due to a tumor in the porta hepatis.
  • He was also diagnosed with SCLC by a fine-needle aspiration biopsy of a lung tumor in the left lower lobe.
  • Both cases were successfully treated with systemic chemotherapy after endoscopic retrograde biliary drainage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23754881.001).
  • [ISSN] 1179-142X
  • [Journal-full-title] International medical case reports journal
  • [ISO-abbreviation] Int Med Case Rep J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3658212
  • [Keywords] NOTNLM ; biliary obstruction / jaundice / metastasis / small-cell lung carcinoma
  •  go-up   go-down


99. Eyigor C, Pirim A, Uyar M: Should interventional pain management in patients with pancreatic cancer be guided by tumor localization? J BUON; 2010 Oct-Dec;15(4):715-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should interventional pain management in patients with pancreatic cancer be guided by tumor localization?
  • Patients were allocated into 2 groups according to the tumor localization, namely group 1 (n=61; patients with pancreatic cancer confined to the head of pancreas), and group 2 (n=55; patients with pancreatic cancer confined to the body or tail of pancreas).
  • CONCLUSION: pain palliation could be achieved by sympathetic block in patients with cancer localized in the head of pancreas while patients with tumor localized in the body and tail experienced sufficient pain palliation by spinal analgesia rather than sympathetic block.
  • [MeSH-major] Anesthetics, Local / therapeutic use. Pain Measurement. Pain, Intractable / drug therapy. Pancreatic Neoplasms / complications
  • [MeSH-minor] Female. Humans. Male. Middle Aged. Nerve Block. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21229635.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Anesthetics, Local
  •  go-up   go-down


100. Choi SH, Hwang HK, Kang CM, Lee WJ: Total pancreaticoduodenectomy and segmental resection of superior mesenteric vein-portal vein confluence with autologous splenic vein graft in mucinous cystadenocarcinoma of the pancreas. JOP; 2010;11(6):638-41
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total pancreaticoduodenectomy and segmental resection of superior mesenteric vein-portal vein confluence with autologous splenic vein graft in mucinous cystadenocarcinoma of the pancreas.
  • CONTEXT: Mucinous cystic tumors occur almost exclusively in middle-aged women and in the body or tail of the pancreas.
  • Mucinous cystadenocarcinoma, a malignant sub-type of mucinous cystic tumors, in the head of the pancreas and in a middle-aged man is extraordinary, and the prognosis and proper management of mucinous cystadenocarcinoma has not been well documented.
  • CASE REPORT: A 52-year-old male patient with a mucinous cystadenocarcinoma approximately 5.5 cm in size in the head of the pancreas underwent a total pancreaticoduodenectomy and segmental resection of the superior mesenteric vein-portal vein confluence with an autologous splenic vein graft due to tumor invasion.
  • His postoperative course was uneventful and he received adjuvant chemotherapy.
  • CONCLUSION: Mucinous cystadenocarcinoma in the head of the pancreas in a middle-aged man is an extremely rare case.
  • [MeSH-minor] Humans. Male. Middle Aged. Tomography, X-Ray Computed. Transplantation, Autologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21068503.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down






Advertisement